




27th AISF PRE-MEETING COURSE


**Emergencies in hepatology:
a critical care approach**

Rome, March 18th, 2026

58th AISF ANNUAL MEETING

Italian Association for the Study of the Liver

Rome, March 19th/20th, 2026



AISF Italian Association for the Study of the Liver



**AISF - Associazione Italiana
per lo Studio del Fegato**

Viale Maresciallo Pilsudski, 118 • 00197 Roma

Tel. 06 86399303 • E-mail info@webaisf.org

Web www.webaisf.org



AISF GOVERNING BOARD

Giacomo Germani, Padua (AISF Secretary)

Roberta D'Ambrosio, Milan

Giacomo Germani, Padua

Stefano Gitto, Florence

Giuseppe Marrone, Rome

Francesco Tovoli, Bologna

Umberto Vespasiani Gentilucci, Rome

CONTENTS

27th AISF PRE-MEETING COURSE

PROGRAM - MARCH 18th, 2026

4

58th AISF ANNUAL MEETING

PROGRAM - MARCH 19th, 2026

7

PROGRAM - MARCH 20th, 2026

17

SESSIONE POSTER

MARCH 19th, 2026

24

MARCH 20th, 2026

40

FACULTY

57

INFORMAZIONI GENERALI

60

ISCRIZIONI - PRE MEETING COURSE

61

E.C.M. - PRE MEETING COURSE

62

ISCRIZIONI - ANNUAL MEETING

63

E.C.M. - ANNUAL MEETING

64



27th AISF PRE-MEETING COURSE 58th AISF ANNUAL MEETING

Il **27° Pre-Meeting AISF**, intitolato “Emergencies in Hepatology: A Critical Care Approach”, si concentra interamente sulla gestione delle urgenze epatologiche, che rappresentano una delle sfide più delicate e ad alto impatto nella pratica clinica quotidiana. Nonostante i notevoli progressi raggiunti nella diagnosi e nel trattamento delle malattie di fegato, esistono ancora numerose condizioni acute caratterizzate da un decorso rapidamente evolutivo, capaci di determinare una significativa morbidità e mortalità se non riconosciute tempestivamente.


Nel corso delle sessioni verranno affrontati i principali scenari critici dell’epatologia moderna: dall’insufficienza epatica acuta e acutamente scompensata alle complicanze improvvise della cirrosi, dalle forme tossicologiche e metaboliche severe ai quadri vascolari acuti, fino alla gestione del paziente epatologico in terapia intensiva, dove la collaborazione multidisciplinare assume un ruolo decisivo.

Il 27° Pre-Meeting AISF nasce quindi con l’obiettivo di fornire un aggiornamento completo, pratico e basato sulle migliori evidenze disponibili, dedicato alle situazioni in cui rapidità decisionale, competenze tecniche e capacità di lavorare in team diventano elementi essenziali.

Il **58° AISF Annual Meeting** si propone come un’occasione di aggiornamento sui progressi più significativi in ambito epatologico, finalizzata alla promozione di un confronto aperto tra clinici esperti, ricercatori e giovani epatologi.

Il programma scientifico, articolato in sessioni di aggiornamento, presentazioni di studi originali e discussioni multidisciplinari, affronta i principali temi di interesse della disciplina: dalle epatopatie croniche alle neoplasie del fegato e delle vie biliari, dalle innovazioni farmacologiche alle nuove metodologie diagnostiche e digitali.

L’evento intende promuovere una riflessione condivisa sulle esigenze che caratterizzano i percorsi di cura e le direzioni future della ricerca, sostenendo il ruolo dell’AISF come punto di riferimento per la comunità scientifica e per la formazione delle nuove generazioni di epatologi.



27th AISF PRE-MEETING COURSE PROGRAM - MARCH 18th, 2026

10:00 **Accreditamento partecipanti e faculty**
10:40

AUDITORIUM

27th AISF PRE-MEETING COURSE Emergencies in hepatology: a critical care approach

10:40 **INTRODUCTION**
11:00 AISF Governing Board

11:00 **SESSION I - ACUTE HEPATITIS
AND ACUTE LIVER FAILURE**
Chairs: R. D'Ambrosio, G. Marrone

11:00 **Acute immune-mediated liver injury:
new challenges for an old paradigm**
A. Lleo

11:15 **Managing severe alcohol-related hepatitis:
are we all on the same page?**
G. Perricone

11:30 **Acute liver failure: from early assessment
to advanced medical support**
S. Martini


11:45 **Liver transplantation for acute liver failure:
is it time for new selection criteria?**
C. Morelli

12:00 **Discussion**

12:20 **STATE OF THE ART LECTURE**
12:50 **Improving outcomes in critically ill liver
patients: the role of clinical care networks**
V. Calvaruso
Introduction: G. Germani

EXHIBITION AREA

12:50 **Lunch**
13:50



27th AISF PRE-MEETING COURSE PROGRAM - MARCH 18th, 2026

AUDITORIUM


- 13:50 **SESSION II - ACUTE COMPLICATIONS
AND ACUTE ON CHRONIC
LIVER FAILURE**
Chairs: P. Caraceni, S. Gitto
- 13:50 **Acute renal dysfunction: updated
definition and treatment options**
S. Piano
- 14:05 **Acute splanchnic vein thrombosis:
medical therapy vs. interventional radiology**
F. Schepis
- 14:20 **ACLF: epidemiology and evolving
standards of care**
G. Zaccherini
- 14:35 **ACLF and liver transplantation:
who benefits most?**
V. Giannelli
- 14:50 **Discussion**

AUDITORIUM

- 15:10 **SESSION III – BLEEDING AND
COAGULOPATHY**
Chairs: F. Tovoli, F. Vizzutti
- 15:10 **Integrating medical and endoscopic
therapies in variceal bleeding**
G. Tosetti
- 15:25 **When endoscopy is not enough:
the role of interventional radiology**
M. Senzolo
- 15:40 **Beyond INR: understanding the rebalanced
haemostasis in liver disease**
V. La Mura
- 15:55 **Discussion**

EXHIBITION AREA

- 16:15 **Coffee Break**
16:45



27th AISF PRE-MEETING COURSE PROGRAM - MARCH 18th, 2026

AUDITORIUM

16:45 **SESSION IV – CRITICAL CARE AND**
18:05 **MULTIDISCIPLINARY MANAGEMENT**

Chairs: G. Svegliati Baroni,
U. Vespasiani Gentilucci

16:45 **Sepsis in cirrhosis: risk stratification
and intervention strategies**

M. Bartoletti

17:00 **Treating alcohol withdrawal syndrome
in the setting of liver disease**

G. Addolorato

17:15 **Pregnancy and liver disease:
managing a complex intersection**

P. Burra

17:30 **ICU care of patients with cirrhosis:
a fine line between utility and futility**

P. Persona

17:45 **Discussion**

18:05 **GENERAL ASSEMBLY 1** (No E.C.M.)

18:10 AISF Governing Board

PARALLEL SESSION (No E.C.M.)

AUDITORIUM

18:15 **Up to date Lectures on Specific Topics /**

19:45 **Up to date Symposium on Specific Topics**

ROOM GH


18:15 **Up to date Lectures on Specific Topics /**

19:45 **Up to date Symposium on Specific Topics**

PININFARINA

18:15 **Up to date Lectures on Specific Topics /**

19:45 **Up to date Symposium on Specific Topics**



58th AISF ANNUAL MEETING PROGRAM - MARCH 19th, 2026

58th AISF ANNUAL MEETING

EARLY MORNING WORKSHOP (No E.C.M.)

ROOM GH

08:00 **NEW PERSPECTIVES ON LIVER**
08:45 **TRANSPLANTATION FOR**
ALCOHOL-RELATED LIVER DISEASE
Chairs: N. De Maria, A. Ferrarese

PININFARINA

08:00 **MULTIDISCIPLINARY MANAGEMENT**
08:45 **OF HCC**
Chairs: C. Mazzairelli, A. Vitale

ROOM A

08:00 **THE EVOLVING CHALLENGE OF**
08:45 **INFECTIONS IN CIRRHOSIS**
Chairs: N. Coppola, V. Zuccaro

AUDITORIUM

08:50 **WELCOME & INTRODUCTION**
09:00 *AISF Governing Board*

09:00 **GENERAL SESSION 1**
10:00 *Chairs: A. Aghemo, L. Miele*

Transjugular Intrahepatic Portosystemic Shunt in Patients with Portosinusoidal Vascular Disorder: A Retrospective Multicentre International Study from the Vascular Liver Diseases Group (VALDIG)


Presenter: Marco Senzolo (Padua)

Authors: L. Turco, F. Schepis, D. Saltini, F. Vizzuti, M. Viganò, S. Fagioli, C. Becchetti, A. Airolti, S. Nardelli, S. Gioia, A. Zanetto, E. Pinto, K. Ferdinande, M.G. Indre, M.C. Morelli, G. Tosetti, F. Santopaulo, N. Pugliese, D. Sacerdoti, M. Senzolo Bologna, Modena, Florence, Bergamo, Milan, Rome, Padua, Pieve Emanuele (MI), Rozzano (MI), Verona

Mechanistic and therapeutic insight into the ATG7 p.V471A variant role in MASLD progression

Presenter: Alessandra Cazzaniga (Milan)

Authors: A. Cazzaniga, S. Frigo, A. Cherubini,



58th AISF ANNUAL MEETING PROGRAM - MARCH 19th, 2026

G. Baselli, L. Cerami, V. Vaira, L. Valenti
Milan, Stockholm (Sweden)

Bulevirtide monotherapy prevents liver decompensation in patients with hdv-related cirrhosis: a case control study with propensity score weighted analysis

Presenter: Pietro Lampertico (Milan)


Authors: E. Degasper, A. De Silvestri, D. Roulot, M.P. Anolli, L. Gheorghe, M. Chitul, C. Schramm, H. Schmidt, M. Jachs, T. Reiberger, J. Foucher, S. Metivier, M. Buti, A. Palom, G. D'Offizi, F. Di Maria, C. Zöllner, F. Tacke, C. Dietz-Fricke, H. Wedemeyer, M. Papatheodoridi, G. Papatheodoridis, I. Carey, K. Agarwal, F. Van Bömmell, M. R. Brunetto, M. Cardoso, E. Rosselli Del Turco, A. Ciancio, S. Lens, Á. Giráldez-Gallego, F. Zoulim, S. Aleman, N. Semmo, A. Mangia, M.N. Hilleret, U. Merle, T.A. Santantonio, N. Coppola, A. Pellicelli, B. Roche, X. Causse, L. D'Alteroche, J. Dumortier, N. Ganne, F. Heluwaert, I. Ollivier, M. Viganò, A. Federico, F. Pileri, M. Maracci, M. Tonnini, J.-P. Arpurt, K. Barange, E. Billaud, S. Pol, A. Gervais, A. Minello, I. Rosa, M. Puoi, J. Flaherty, P. Lampertico
Milan, Pavia, Bobigny (France), Bucarest (Romania).

Essen (Germany), Vienna (Austria), Bordeaux (France), Toulouse (France), Barcelona (Spain), Rome, Berlin (Germany), Hannover (Germany), Athens (Greece), London (UK), Leipzig (Germany), Pisa, Amadora (Portugal), Bologna, Turin, Sevilla (Spain), Lyon (France), Stockholm (Sweden), Bern (Switzerland), San Giovanni Rotondo (FG), Grenoble (France), Heidelberg (Germany), Foggia, Naples, Villejuif (France), Orléans (France), Tours (France), Annecy (France), Caen (France), Bergamo, Modena, Ancona, Avignon (France), Paris (France), Dijon (France), Créteil (France), Foster City (USA)

Complete pathological response following liver transplatation for hepatocellular carcinoma (hepaclear). Absolute benefit or waste of resources?

Presenter: Giammauro Berardi (Rome)

Authors: G. Berardi, A. Cucchetti, C. Sposito, A. Vitale, M. Colasanti, L. Di Cesare, M. Serenari, S. Di Sandro, F. Falaschi, G. Vennarecci, F. Di Benedetto, U. Cillo, M. Cescon, V. Mazzaferro, G.M. Ettorre
Rome, Forlì, Milan, Padua, Bologna, Modena, Naples



58th AISF ANNUAL MEETING PROGRAM - MARCH 19th, 2026

Exploring PD-L1–Induced Immune Remodeling in Cholangiocarcinoma through a Human-Derived Organ-on-Chip System

Presenter: Sofia Buzzi (Rozzano, MI)

Authors: S. Buzzi, M.A. Polidoro, G. Montorsi,
C. Soldani, B. Franceschini, A. Gazzillo, A. Cammarota,
F. Milana, G. Torzilli, P. Occhetta, M. Rasponi, A. Lleo
Rozzano (MI), Milan

10:00 **STATE OF THE ART LECTURE**

10:30 **Redefining the hepatologist's role
in the (dys)metabolic era: challenges
and opportunities**

Z. Younossi

Presenter: E. Bugianesi

EXHIBITION AREA

10:30 **Coffee Break**

11:00

AUDITORIUM

11:00 **SYMPOSIUM I - STEATOTIC LIVER
DISEASE AND ALCOHOL-RELATED
LIVER DISEASE**


Chairs: A. Gasbarrini, S. Petta

11:00 **Targeting the liver and beyond: current
and emerging therapies for MASLD**
F. Marra

11:15 **MetALD: a diagnostic dilemma
or a new disease entity?**
A. Federico

11:30 **New horizons in ArLD management:
integrating emerging therapies
into clinical care**
L. Abenavoli

11:45 **Discussion**



58th AISF ANNUAL MEETING PROGRAM - MARCH 19th, 2026

12:00 **POLICY, PUBLIC HEALTH
AND ADVOCACY NETWORK**
National strategies for prevention
of liver disease: from policy to practice
M. Conforti, G. Germani, L. Kondili, TBC

12:30 **AISF CAREER AWARD** (No E.C.M.)
12:45 **A.L. Zignego**
Presenter: *M. Brunetto*

EXHIBITION AREA

12:45 **LUNCH & POSTER VIEW**
13:45

AUDITORIUM

13:45 **SYMPOSIUM**
14:45 **COMMISSIONE PERMANENTE
TRAPIANTO (CPT)**
**ONE PATIENT, MANY VOICES:
CHALLENGES IN MULTIDISCIPLINARY
TRANSPLANT CARE**

Chairs: *C. Becchetti, D. Pagano,
G. Svegliati Baroni*

Introduction

V. Giannelli

Diabetes and obesity around liver
transplantation: innovative
pharmacological and surgical strategies
C. Morelli

Tailoring immunosuppression:
when etiology shapes therapy
G. Marrone



58th AISF ANNUAL MEETING PROGRAM - MARCH 19th, 2026

Rare indications for adult liver
transplantation: a multidimensional
approach to improve outcomes

P. Toniutto

Take Home Messages

P. Burra

SALA DELL'ARCHITETTURA + SALA DELL'EDITORIA

13:45 **PORTAL HYPERTENSION LAB** (No E.C.M.)

14:45 *F. Schepis, M. Senzolo, L. Turco, F. Vizzutti*

AUDITORIUM

14:45 **AISF-CLEO JOINT SESSION**

15:30 **ADVANCES IN THE MULTIDIMENSIONAL
MANAGEMENT OF CIRRHOSIS**

Chairs: *G. Germani, R. Sacco*

14:45 **Practical approaches to sarcopenia
evaluation in cirrhotic patients**

P. Gallo


14:55 **Disease-modifying treatments
in cirrhosis: an update**

E. Degasperi

15:05 **The role of digital health
in cirrhosis management**

M. Distefano

15:15 **Discussion**



58th AISF ANNUAL MEETING PROGRAM - MARCH 19th, 2026

ROOM GH

14:45 **PARALLEL SESSION 1**

15:30 Chairs: A. Armandi, N. Cazzagon

A prospective multicenter study to examine the impact of acquired and genetic predictors on Hepatocellular carcinoma risk in patients with advanced MASLD

Presenter: Stefania Mira (Milan)

Authors: S. Mira, S. Pelusi, L. Miano, F. Malvestiti, G. Periti, L. Ronzoni, M. Saracino, R. D'Ambrosio, L. Miele, A. Liguori, E. Bugianesi, C. Rosso, P. Dongiovanni, G. Soardo, S. Petta, G. Pennisi, U. Vespasiani Gentilucci, F. Tavaglione, A. Federico, F.P. Russo, P. Zanaga, M. Masarone, D. Prati, L. Valenti Milan, Pavia, Rome, London (UK), Torino, Udine, Palermo, La Jolla (USA), Naples, Padua, Baronissi (SA)

Mapping the hepatic mtDNA genomic landscape in patients with MASLD: The Era of GPT-4 Artificial Intelligence

Presenter: Miriam Longo (Milan)

Authors: M. Longo, E. Paolini, M. Meroni, A.L. Fracanzani, P. Dongiovanni Milan

Diagnostic yield and clinical correlates of inherited cholestatic gene variants in adult-onset cryptogenic cholestasis: an Italian multicentre experience


Presenter: Filippo Gabrielli (Modena)

Authors: F. Gabrielli, F. Caputo, A. Bono, F. Ravaioli, S. Ferrari, A. Vaisfeld, C. Paone, L. Turco, M.C. Morelli, I. Costa, A. Bruni, L. Colecchia, E. Dajti, F. Girolami, E. Bernasconi, A. Centofanti, A. Conti, P. Andreone, F. Azzaroli, F. Piscaglia, G. Vitale Modena, Bologna

Longitudinal changes of liver elastography, FIB4 and Agile3+ add prognostic significance to baseline values in patients with Metabolic dysfunction Associated Steatotic Liver Disease (MASLD)

Presenter: Antonio Liguori (Rome)

Authors: A. Liguori, L. Petrucci, F. Pantaleo, F. S.M. Youssef, G. Marrone, M. Biolato, M. Pompili, A. Grieco, A. Gasbarrini, L. Miele Rome



58th AISF ANNUAL MEETING PROGRAM - MARCH 19th, 2026

PININFARINA

14:45 **PARALLEL SESSION 2**


15:30 Chairs: A. Gerussi, C. Balsano

The Burden of Extrahepatic Comorbidities in Primary Biliary Cholangitis: Insights from the Italian National PBC Registry

Presenter: Nora Cazzagon (Padua)

Authors: N. Cazzagon, A. De Vincentis, M. Benatti, E. Nofit, F. Terracciani, E. Catanzaro, T. Zappitelli, F. Bonarrigo, G. Figorilli, M. Peviani, L. Abenavoli, G. Scarlata, G. Alagna, D. Alvaro, S. Nardelli, D. Montecalvo, P. Andreone, F. Gabrielli, F. Azzaroli, E. Dajti, L. Baiocchi, P. Carni, F. Bellanti, S. Quiete, M.C. Bragazzi, R. Venere, F. Bronte, A. Affronti, M. Brunetto, B. Coco, V. Calvaruso, V. Di Marco, M.C. Neglia, F. Capelli, L. Pitotti, A. Castellaneta, A. De Feudis, I. Cavalli, A. Gobbi, L. Chessa, F. Pes, R. Chiavaroli, M. Graffeo, F. Cerini, F. Pavan, S. Crocè, F. Masutti, C. Cusumano, N. Passigato, S. Di Cesare, A. Granito, F. Piscaglia, N. Dal Bo', V. Vanin, L. Fabris, A. Lasagni, S. Fagioli, M. Viganò, A. Federico, F. Di Nardo, E. Giannini, S. Labanca, G. Niro, R. Cotugno, E. Lynch, A. Galli, P. Lampertico,

E. Degasperi, P. Lecis, A. Meneghetti, A. Lleo, F. Colapietro, A. Mangia, V. Piazzolla, F. Marra, F. Biagi, M. Marzioni, L. Maroni, A. Mega, L. Miele, F. Ponziani, G. Missale, A. Orlandini, F. Morisco, V. Cossiga, G. Nardone, A. Rocco, V. Palitti, M. Persico, M. Masarone, T. Sarcina, G. Raimondo, C. Saitta, C. Ricci, P. Poisa, C. Rigamonti, G. Manfredi, M. Russello, M. Cannavò, S. Schianchi, M. Beltrami, C. Simoni, E. Masciocchi, F. Losito, R. Cozzolongo, E. Vanni, G. Vettori, L. Moser, L. Surace, E. Falbo, R. Viganò, F. D'Amico, G. Vitale, M.C. Morelli, T. Zolfino, C. Scudu, A. Gerussi, L. Cristofori, M. Carbone, P. Invernizzi, U. Vespasiani Gentilucci Padua, Rome, Monza, Catanzaro, Sassari, Modena, Bologna, Foggia, Latina, Palermo, Pisa, Bari, Cremona, Monserrato, Brescia, Trieste, Verona, Treviso, Bergamo, Naples, Genoa, San Giovanni Rotondo (FG), Florence, Milan, Bassano del Grappa, Rozzano(MI), Pieve Emanuele (MI), Ancona, Bolzano, Parma, Pescara, Salerno, Messina, Novara, Catania, Reggio Emilia, Gallarate, Castellana Grotte (BA), Turin, Trento, Cagliari



58th AISF ANNUAL MEETING PROGRAM - MARCH 19th, 2026

A multimodal artificial intelligence approach for predicting therapeutic decisions in hepatocellular carcinoma: integrating clinical and imaging data

Presenter: *Ciro Celsa* (Palermo)

Authors: *C. Celsa, S. Contino, M. Giuffrè, A. Grova, G. Di Maria, R. Cannella, L. Cruciata, R. Ciccia, M. Salvato, S. Restuccia, G. Giusino, A. Quartararo, G. Cusimano, A. Sparacino, V. Gaudio, C. La Mantia, F. Mercurio, S. Kresevic, M. Ajcevic, G. Cabibbo, G. Cirrincione, R. Pirrone, C. Cammà*
Palermo, London (UK), Yale, New Haven, Connecticut, USA, Trieste, Amiens (France)

Large extracellular vesicles fingerprint of PSVD reveals an endothelial-platelet activation and immune dysregulation

Presenter: *Elisa Pinto* (Padua)

Authors: *E. Pinto, A. Zanetto, K. Ferdinande, E. Campello, C. Bulato, S. Toffanin, S. Gavasso, P. Simioni, M. Senzolo*
Padua

SARCIRAM: A Pilot Study On The Impact Of Hydroxiram D Supplementation On Sarcopenia In Patients With Liver Cirrhosis

Presenter: *Paolo Gallo* (Rome)

Authors: *P. Gallo, L. Santoro, D. Marcelli, V. Flagiello, F. Terracciani, A. Falcomatà, A. De Vincentis, A. Picardi, U. Vespasiani-Gentilucci*
Rome

AUDITORIUM

15:30 **GENERAL ASSEMBLY 2** (No E.C.M.)

15:45 AISF Governing Board

58th AISF ANNUAL MEETING PROGRAM - MARCH 19th, 2026

AUDITORIUM

- 15:45 **SYMPOSIUM II - VIRAL**
16:45 **HEPATITIS AND CASCADE OF CARE**
IN 2026: WHERE DO WE STAND?
Chairs: B. Coco, P. Lampertico
- 15:45 **Advances and unmet needs in HCV,**
HBV and HDV screening
F.P. Russo
- 16:00 **Linkage to care: addressing obstacles**
to bridge the gap
M. Masarone
- 16:15 **Personalized treatment of viral hepatitis:**
overcoming past barriers
M.R. Brunetto
- 16:30 **Discussion**

16:45 **GENERAL SESSION 2**

17:45 Chairs: C. Cammà, L. Valenti

Development of new criteria for early response
to terlipressin and albumin in patient with
Hepatorenal Syndrome - Acute Kidney Injury

Presenter: Valeria Calvino (Padua)

Authors: V. Calvino, S. Incicco, R. Gagliardi,
N. Zeni, G. Antonacci, C.G. Gambino, M. Tonon,
P. Angeli, S.S. Piano
Padua


Microbiota-driven break of B cell tolerance
promotes spontaneous anti-HBsAg seroconversion
in HBV transgenic mice

Presenter: Valeria Fumagalli (Milan)

M. Grillo, C. Perucchini, P. Di Lucia, C. Beccaria,
C. Abbot, M. Ravà, Giustini, E. Bono, S. Becattini,
L. Guidotti, V. Fumagalli, M. Iannacone'
Milan, Genoa

Evaluating Non-invasive Eligibility Criteria for
Resmetirom in Metabolic Dysfunction- Associated
Steatotic Liver Disease (MASLD): Real-world Data
from an Italian Multicentric Cohort

Presenter: Nicola Pugliese (Rozzano, MI)



58th AISF ANNUAL MEETING PROGRAM - MARCH 19th, 2026

Authors: N. Pugliese, D. Polverini, A. Bertazzoni, F. Cerini, R. Lombardi, G. Pennisi, S. De Nicola, C. Masetti, A.L. Fracanzani, M. Viganò, S. Petta, A. Aghemo
Rozzano (MI), Milan, Palermo, Bergamo

Uncovering the role of cell-intrinsic PD-1 in the response to PD-1 blockade in hepatocellular carcinoma

Presenter: Andrea Arleo (Bologna)

Authors: A. Arleo, A. Montagner, C.S. Cioroianu, F. Vasuri, F. Piscaglia, L. Gramantieri, C. Giovannini
Bologna, Ravenna

Liver Transplantation for Wilson's Disease: a study from the ELTR database

Presenter: Alberto Ferrarese (Padua)

Authors: A. Ferrarese, F. Pelizzaro, R. Adam, S. Darwish Murad, V. Karam, S. Yilmaz, M. Heneghan, M. Grat, D. Mirza, M. Schmelzle, D. Cherqui, M. Zeytunlu, J. Pratschke, A. Paul, G. Berlakovich, F.P. Russo, A. Zanetto, N. Cazzagon, G. Germani, P. Burra
Padua, Villejuif (France), Rotterdam (Netherlands), Paris (France), Malatya (Turkey), London (UK), Warsaw (Poland), Birmingham (UK), Hannover (Germany), Izmir (Turkey), Berlin (Germany), Essen (Germany), Wien (Austria)

PARALLEL SESSION (No E.C.M.)

AUDITORIUM

17:50 Up to date Lectures on Specific Topics /
19:20 Up to date Symposium on Specific Topics

ROOM GH

17:50 Up to date Lectures on Specific Topics /
19:20 Up to date Symposium on Specific Topics

PININFARINA

17:50 Up to date Lectures on Specific Topics /
19:20 Up to date Symposium on Specific Topics

AUDITORIUM

09:00 **GENERAL SESSION 3**

10:00 Chairs: S. Montagnese, F. Piscaglia

Longitudinal Assessment of Body Composition and Its Prognostic Impact After TIPS in Cirrhosis: A Prospective Multicentre study (NutriTIPS group)

Presenter: Simone Di Cola (Rome)

Authors: S. Di Cola, J. Gazda, D. Saltini, G. Polidori, C. Sorgenti, A. Mastro, L. Maruzzelli, G. Cusi, A. Barrancotto, L. Lapenna, F. Gentili, R. Miraglia, S. Nardelli, S. Gioia, F. Vizzutti, F. Schepis, M. Merli
Rome, Italy, Kosice (Slovakia), Modena, Florence, Palermo

Prognostic impact of pulmonary hypertension phenotypes and severity in asymptomatic patients with compensated cirrhosis: insights from a large cohort


Presenter: Dario Saltini (Modena)

Authors: D. Saltini, A. Piscopo, T. Guasconi, M. Bianchini, A. Salomè Velasco Mayorga, G. Catania, N. Giglio, F. Scianò, F. Milosa, M.R. Critelli, A. Colecchia, F. Schepis
Modena

Biochemical Response Criteria Predict Transplant-Free Survival Across Disease Stages in Primary Biliary Cholangitis: Findings From the FiOCA Study

Presenter: Vincenzo Ronca (Pieve Emanuele, MI)

Authors: V. Ronca, A. De Vincentis, A. Tanaka, C. Corpechot, P. Trivedi, F. Terracciani, L. Cristoferi, G. Cancado, M. Scaravaglio, N. Cazzagon, N. Abbas, K. Olsen, S. Rodriguez-Tajes, A. Martins, F. Colapietro, M.C. Londoño, N. Gatselis, V. Lygoura, E. Lytvyak, A. Montano-Loza, A. Gerussi, E. Culver, G. Dalekos, D. D'Amato, A. van der Meer, F. Nevens, E. Zigmond, V. Calvaruso, L. Sierra, R. Barba, A. Bonder, A. Villamil, X. Verhelst, C. Levy, H. Ytting, R. Viganò, M. Viganò, A. Lleo, P. Invernizzi, U. Vespasiani-Gentilucci, G. Hirschfield, B. Hansen, M. Carbone
Pieve Emanuele (MI), Rozzano (MI), Rome, Padua, Palermo, Milan, Bergamo, Monza, Tokyo (Japan), Birmingham (UK), Belo Horizonte (Brazil), Miami (USA), Larissa (Greece), Edmonton (Canada), Oxford (UK), Rotterdam (The Netherlands), Leuven (Belgium), Tel Aviv (Israel), Boston (USA), Buenos Aires (Argentina), Ghent (Belgium), Copenhagen (Denmark), Toronto (Canada)



58th AISF ANNUAL MEETING PROGRAM - MARCH 20th, 2026

PNPLA3 beyond the liver: exploring its impact on body composition in MASLD

Presenter: Francesca Alletto (Milan)

Authors: F. Alletto, A. Cespiati, R. Lombardo, F. Cinque, D. Smith, E. Pulixi, E. Fatta, P. Dongiovanni, P. Tarantini, M. Meroni, A.L. Fracanzani
Milan, Busto Arsizio (VA)

Prognostic role of acute clinical clusters of presentation in patient with HCC admitted in the ED

Presenter: Leonardo Stella (Rome)

Authors: L. Stella, G. Marrone, A. Liguori, L. Miele, M. Biolato, M. Pompili, A. Gasbarrini, F. Franceschi, F.R. Ponziani, M. Covino
Rome

10:00 STATE OF THE ART LECTURE

10:30 Targeting the gut-liver-brain axis: contemporary approaches to HE

D. Shawcross

Presenter: A. Lleo

10:30 BEST PAPER BASIC (No E.C.M.)

10:45 *V. La Mura, V. Ronca*

BEST PAPER CLINICAL (No E.C.M.)

Q. Lai, F. Morisco

EXHIBITION AREA

10:45 Coffee Break

11:15

ROOM GH

11:15 PARALLEL SESSION 3

12:00 *Chairs: S. Fagioli, F.R. Ponziani*

Performances of Baveno VII AND AASLD 2024 criteria for detecting gastroesophageal varices in untreated patients with HDV-related cirrhosis

Presenter: Maria Paola Anolli (Milan)

Authors: M.P. Anolli, E. Degasperi, G. Tosetti, L. Gheorghe, A. Loglio, A. Ciano, G. D'Offizi, M. Jachs, C. Schramm, M.R. Brunetto, F. Van Bömmel, S. Zaltron, L. Turco, C. Zöllner, T.A. Santantonio, I. Carey, A. Federico, L. Sarmati, M. Buti, M. Cardoso,

F. Morisco, M. Papatheodoridi, F.P. Russo, A. Mangia, P. Toniutto, N. Coppola, C. Dietz-Fricke, J. Dumortier, E.G. Giannini, E. Rosselli Del Turco, S. Aleman, S. De Nicola, P. Gatti, M. Maracci, L. Marinaro, M. Milella, A. Pellicelli, B. Pinchera, M. Puoti, D. Roulot, L.S. Crocè, I. Maida, U. Merle, A. Pan, P. Torre, F. Piler, A. Romano, M. Tonnini, P. Vitiello, R. Zampino, P. Lampertico
Milan, Bucarest (Romania), Bergamo, Turin, Rome, Vienna (Austria), Essen (Germany), Pisa, Leipzig (Germany), Brescia, Bologna, Berlin (Germany), Foggia, London (UK), Naples, Barcelona (Spain), Amadora (Portugal), Athens (Greece), Padua, San Giovanni Rotondo, Udine, Hannover (Germany), Lyon (France), Genoa, Stockholm (Sweden), Rozzano, Brindisi, Ancona, Bari, Trieste, Sassari, Heidelberg (Germany), Cremona, Baronissi, Modena, Busto Arsizio (VA)

Transjugular intrahepatic portosystemic shunt for refractory hepatic hydrothorax in patients with cirrhosis: a multicenter European study

Presenter: Carlo Alessandria (Turin)

Authors: M. Tizzani, G.P. Caviglia, L. Téllez, S. Geisselbrecht, F. Vizzutti, M. Reincke, C. Becchetti, L. Maruzzelli, D. Saltini, M. Rudler, K. Ferdinande, E. Pompili, H. Larrue, G. Tosetti, S. Nardelli,

D. Campion, J. Donate, A. Tiede, S. Aspite, M. Schultheiss, M. Solcia, A. Olavarria, E. Bugianesi, G. Svegliati Baroni, M. Viganò, S. Piano, P. Toniutto, O. Riggio, V. La Mura, C. Bureau, P. Caraceni, M. Senzolo, D. Thabut, F. Schepis, R. Miraglia, A. Airolidi, D. Bettinger, F. Marra, B. Maasoumy, A. Albillos, A. Marzano, C. Alessandria
Turin, Madrid (Spain), Hannover (Germany), Florence, Freiburg (Germany), Milan, Palermo, Modena, Paris (France), Padua, Bologna, Toulouse (France), Rome, Ancona, Bergamo, Udine

Heterogeneous cardiometabolic patterns influence hepatocellular carcinoma risk and trajectories in advanced fibrosis-affected MASLD patients

Presenter: Mario Romeo (Caserta)

Authors: M. Romeo, M. Dallio, F. Di Nardo, C. Napolitano, P. Vaia, C. Basile, A. Scafuri, G. Martinelli, M. Niosi, A. Federico
Caserta

Effective prevention of further complications of portal-hypertension is independent of TIPS under-dilation

Presenter: Davide Roccarina (Florence)

Authors: D. Roccarina, D. Saltini, M. Senzolo,



58th AISF ANNUAL MEETING PROGRAM - MARCH 20th, 2026

S. Nardelli, I. Scami, T. Zurli, C. Caporali, M. Rosi, V. Adotti, M. Bianchini, L. Biribin, S. Gioia, S. Aspite, L. Ragozzino, T. Guasconi, F. Casari, A. Piscopo, F. Pindozzi, S. Gitto, A. Luca Annese, G. Gabbani, M. Gaggini, K. Ferdinande, E. Casamassima, M. Merli, L. Ridola, O. Riggio, F. Fanelli, C. Mangini, F. Marra, S. Montagnese, F. Schepis, F. Vizzutti
Florence, Modena, Padua, Pisa, Rome

PININFARINA

11:15 **PARALLEL SESSION 4**

12:00 Chairs: M. Carbone, M. Rendina

Real-world experience of fibrates as second-line therapies in patients with primary biliary cholangitis: data from the Italian PBC Registry

Presenter: Laura Cristoferi (Monza)

Authors: L. Cristoferi, E. Nofit, A. Nardi, N. Cazzagon, E. Bonaiuto, P. Lampertico, E. Degasperis, V. Calvaruso, M. Neglia, G. Genova, V. Di Marco, U. Vespasiani Gentilucci, F. Terracciani, A. Lleo, F. Colapietro, E. Vanni, A. Risso, S. Fagioli, F. Azzaroli, E. Daijti, F. Losito, R. Cozzolongo, R. Viganò, F. D'Amico, F. Morisco, V. Cossiga, M. Russello, M. Cannavò,

A. Castellaneta, A. De Feudis, M. Brunetto, B. Coco, M. Marziani, L. Maroni, E.G. Giannini, S. Labanca, . Cerini, F. Pavan, V. Pace Palitti, A. Andreone, F. Gabrielli, C. Rigamonti, G. Manfredi, G. Vitale, M.C. Morelli, G. Niro, R. Cotugno, L. Napoli, F. Foschi, A. Galli, A. Curto, E.N. Lynch, M. Persico, M. Masarone, D. D'Amato, A. Gerussi, G. Missale, A. Orlandini, G. Alagna, A. Granito, F. Piscaglia, G. Raimondo, C. Saitta, D. Alvaro, S. Nardelli, D. Montecalvo, F. Bellanti, S. Quiete, G. Vettori, L. Moser, A. Mega, M. Zoeschg, A. Federico, F. Di Nardo, F.R. Ponziani, F. Fianchi, I. Cavalli, A. Gobbi, C. Cusumano, C. Agnolon, N. Passigato, F. Capelli, L. Pitotti, L. Baiocchi, P. Carni, L. Surace, E. Falbo, T. Zolfino, C. Scudu, C. Ricci, P. Poisa, L. Fabris, A. Lasagni, P. Lecis, A. Meneghetti, L. Abenavoli, G.G.M. Scarlata, A. Baragiotta, L. Chessa, F. Pes, S.L. Crocè, F. Masutti, M.C. Bragazzi, R. Venere, F. Bronte, A. Affronti, P. Invernizzi, M. Carbone, M. Viganò
Monza, Rome, Padova, Milano, Palermo, Rozzano, Torino, Bergamo, Bologna, Castellana Grotte, Napoli, Catania, Bari, Pisa, Ancona, Genova, Pescara, Modena, Novara, San Giovanni Rotondo (FG), Faenza, Firenze, Salerno, Parma, Sassari, Messina, Foggia, Trento, Bolzano, Cremona, Verona, Legnano, Lamezia Terme,

Cagliari, Brescia, Bassano del Grappa, Catanzaro, Pordenone, Trieste, Latina

Endoscopic Ultrasound-Guided Portal Venous Pressure (EUS-PVP) Measurement for Predicting Outcomes in patients with suspected portal hypertension: A Bicentric Clinical Study

Presenter: Giuseppe Tarantino (Ancona)

Authors: F. Santopaolo, G. Tarantino, M. Marzioni, L. Salvi, F. Martini, A. Alessandrini, M. Dalla Bella, C. Cavallo, L. Giuli, B.E. Annicchiarico, G. Rizzatti, G. Tripodi, A. Benedetti, A. Larghi
Rome, Ancona

Impact of non-selective beta-blockers on acute kidney injury outcomes in decompensated cirrhosis

Presenter: Simone Incicco (Padua)


Authors: S. Incicco, K.R. Patidar, A. Juanola, A.T. Ma, A. Barone, A.V. Kulkarni, J.L. Pérez Hernández, S. K. Asrani, B. Wentworth, C. Alessandria, N.A. Abdelkader, Y.J. Wong, Q. Xie, N.T. Pyrsopoulos, S.E. Kim, Y. Fouad, A. Torre, E. Cerda Reyes, J. Díaz-Ferrer, R. Maiwall, D.A. Simonetto, M. Papp, E.S. Orman, G. Perricone, C. Solé, C. M. Lange, A.Q. Farias, G. Pereira, S. Marciano, P. Caraceni, T. Thévenot, N. Verma, J.H. Kim, J.D. Vorobioff,

J. Cordova-Gallardo, V. Ivashkin, R. Maan, J.P. Roblero, C. Toledo, S. Gioia, E. Fassio, M. Marino, P. Nabilou, V. Vargas, M. Merli, L. L. Goncalves, L. Rabinowich, A. Krag, L. Balcar, A. Gadano, F. Durand, S.K. Sarin, P. Ginès, P. Angeli, E. Solà, S. Piano
Padua, Turin, Milan, Bologna, Rome, São Paulo (Brasil), Buenos Aires (Argentina), Barcelona (Spain), Sabadell (Spain), Munich (Germany), Rio de Janeiro (Brasil), Besançon (France), Rosario (Argentina), Hvidovre (Denmark), Vitória (Brasil), Tel Aviv (Israel), Odense (Denmark), Vienna (Austria), Stanford (USA)

Metabolic Reprogramming in MASH-Related HCC: The Emerging Role of G6PD as a Biomarker and Target

Presenter: Jessica Nurcis (Turin)

Authors: J. Nurcis, B. Foglia, M. Maggiora, A. Gambella, U. Chianese, C. Bocca, G.P. Caviglia, A. Caddeo, R. Bendetti, F. Bossi, P. Carucci, S. Gaia, A. Perra, R. Romagnoli, E. Bugianesi, L. Altucci, L. Varricchio, M. Parola, M. Kowalick, S. Rapposelli, S. Cannito
Turin, Genoa, Naples, Cagliari, Pisa



58th AISF ANNUAL MEETING PROGRAM - MARCH 20th, 2026

AUDITORIUM

- 12:00 **SYMPOSIUM III - AUTOIMMUNE
AND CHOLESTATIC LIVER DISEASES**
Chairs: V. Calvaruso, P. Invernizzi
- 12:00 **Emerging therapeutic strategies in PSC:
current and advanced future horizons**
D. Alvaro
- 12:15 **Comprehensive care in PBC:
recognizing, measuring, and intervening**
C. Rigamonti
- 12:30 **Uncovering genetic cholestasis in adults:
diagnostic pathways and targeted therapy**
M. Viganò
- 12:45 **Discussion**

EXHIBITION AREA

- 13:00 **LUNCH & POSTER VIEW**
14:00

SALA DELL'ARCHITETTURA + SALA DELL'EDITORIA

- 13:00 **PORTAL HYPERTENSION LAB** (No E.C.M.)
14:00 D. Saltini, F. Schepis, M. Senzolo, A. Zanetto

AUDITORIUM

- 14:00 **GENERAL ASSEMBLY 3** (No E.C.M.)
15:00 AISF Governing Board


58th AISF ANNUAL MEETING PROGRAM - MARCH 20th, 2026

AUDITORIUM

- 15:00 **SYMPOSIUM IV - LIVER ONCOLOGY**
16:00 Chairs: G. Cabibbo, E. Giannini
- 15:00 **Immuno-downstaging in HCC: expanding boundaries of liver transplant eligibility**
S. Bhoori
- 15:15 **The role of TARE in patients with HCC or cholangiocarcinoma: where do we stand?**
L. Crocetti
- 15:30 **Liver transplantation for cholangiocarcinoma: from exception to consensus**
E. Gringeri
- 15:45 **Discussion**

AUDITORIUM

- 16:00 **2 PREMI BEST ORAL** (No E.C.M.)
16:15 M. Persico, G. Squadrito
- 2 PREMI BEST POSTERS** (No E.C.M.)
L. Cristoferi, A. Loglio
- 16:15 **GENERAL ASSEMBLY 4** (No E.C.M.)
16:30 AISF Governing Board
- 16:30 **CLOSING REMARKS**
16:40 AISF Governing Board



58th AISF ANNUAL MEETING

SESSIONE POSTER - MARCH 19th, 2026

1. How Liver Function Defines Real-World Outcomes with Atezolizumab–Bevacizumab in uHCC

L. Stella, A. Gasbarrini, M. Pallozzi, L. Cerrito, C. Hollande, H. Fakouri, F.R. Ponziani, M. Bouattour
Rome, Clichy (France)

2. Chronic exposure to Bisphenol A triggers trained immunity-related pathways and innate remodeling in the pathogenesis of Metabolic dysfunction-associated steatotic liver disease (MASLD)

M. Dallio, M. Romeo, F. Di Nardo, A. Silvestrin, G. Senese, C. Napolitano, G. Martinelli, L. Di Puerto, A. Coppola, A. Federico
Naples

3. Prolonged Intake of Bicarbonate-Sulfate-Calcium-Magnesium Mineral Water Improves MASLD Outcomes via Modulation of Gut Barrier, Inflammation, and Oxidative Stress

M. Dallio, C. Napolitano, M. Romeo, F. Di Nardo, P. Vaia, C. Basile, G. Martinelli, S. Olivieri, L.M. Vitale, A. Federico
Naples

4. A head-to-head comparison of MAFLD and MASLD diagnostic criteria in estimating the risk of hepatocellular carcinoma (HCC) in HCV patients achieving sustained virological response

F. Di Nardo, M. Dallio, M. Romeo, C. Napolitano, P. Vaia, C. Basile, A. Scafuri, L.M. Vitale, M. Niosi, A. Federico
Naples

5. Baseline anti-mitochondrial antibody titre in addition to gamma-glutamyltranspeptidase and alanine-aminotransferase serum levels anticipate future primary biliary cholangitis development.

D. Bitetto, C. Fabris, E. Fornasiere, E. Fumolo, E. Garlatti Costa, S. Cmet, P. Toniutto - Udin

6. Hepatic antifibrotic response by fibrogenesis markers in in patients with MASLD undergoing a 6-month randomized dietary trial.

A. Armandi, R. Surabattula, D. J. Leeming, G.P. Caviglia, M. Guariglia, C. Rosso, E. Dileo, F. Bioletto, I. Goitre, V. Ponzio, F. Saba, K. Gjini, D.G. Ribaldone, S. Myneni, S. Bo, D. Schuppan, E. Bugianesi - Turin, Mainz (Germany), Herlev (Denmark), Boston (USA)

7. Involvement of the hERG1 potassium channel in cholangiocarcinoma cell biology

C. Duranti, C. Capitani, R. Colasurdo, T. Lottini, P. Ostano, A. Tani, J. Iorio, D. Nosi, D. Bani, A. Arcangeli, C. Raggi, E. Frediani, F. Margheri, M. Pastore, F. Marra, L. Maggi, A. Vanni, D. Guasti
Florence, Biella

8. Portal–Peripheral miRNA Signature Reveals a Chronic Pro-Inflammatory Trap in the Portal District linked to local Increased Endothelial NLRP3 Inflammasome Activity in Cirrhosis

K. Ferdinande, A. Zanetto, M. Carron, G. Barbiero, M. Battistel, S. Groff, S. Shalaby, R. Cardin, M. Senzolo
Padua, Barcelona (Spain)

9. PNPLA3 p.I148M variant affects lipid droplets number and composition in patient-derived liver organoids

E. Casirati, A. Cherubini, L. Cerami, F. Carli, D. Dondossola, A. Gastaldelli, D. Prati, L. Valenti
Milan, Pisa

10. Periportal immune niches shaping intrahepatic CD8⁺ T cells immunity


F. Andreatta, E. Pensieri, C. Laura, M. Genua, D.L. Pietro, E. Bono, F. Iannucci, G. Eschillo, L. Giustini, C. Perrucchini, P. Delfino, C. Beccaria, L. Guidotti, M. Iannacone
Milan

11. An ultrasound/elastography screening experience for metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a High-Risk Population: prevalence and factors associated with MASLD and liver Fibrosis

F. Gabrielli, G. Piazza, S. Lugari, A. Cavicchioli, C. Felicani, A. Rudilosso, M. Bondi, C. Valenti, L. Valerio, C. Pacchioni, C. Greco, D. Santi, G. Spaggiari, M. Simoni, F. Carubbi, L. Bertarini, F. Pellati, P. Andreone, P. Ventura, F. Nascimbeni
Modena

12. Referral strategies in intermediate-risk FIB-4 patients: can longitudinal monitoring reduce FibroScan® use without missing advanced fibrosis?

G.P. Caviglia, A. Armandi, M. Guariglia, E. Dileo, F. Saba, E. Bugianesi
Turin



58th AISF ANNUAL MEETING

SESSIONE POSTER - MARCH 19th, 2026

13. Neurofilament Light Chain Proteins are a sensitive biomarker of neuronal damage in hepatic encephalopathy

C. Asero, F. Polito, M. S. Franzè, A. Battaglia, C. Ligresti, T. Maltese, M. Aguenouz, V. Macaione, I. Cacciola Messina, Palermo

14. Predicting early progression in advanced hepatocellular carcinoma treated with atezolizumab-bevacizumab: a multimodal deep learning approach

C. Celsa, S. Contino, R. Cannella, R. Ciccìa, G. Crescimanno, L. Cruciata, S. Restuccia, G. Giusino, G. Cusimano, S. Calascibetta, A. Quartararo, G. Cabibbo, G. Cirrincione, R. Pirrone, C. Cammà Palermo, Amiens (France)

15. Multimodal Deep Learning Model for BCLC Staging of Hepatocellular Carcinoma: Integration of Radiological Imaging and Clinical Data

C. Celsa, S. Contino, R. Cannella, M. Salvato, L. Cruciata, S. Restuccia, G. Giusino, G. Cusimano, S. Calascibetta, A. Quartararo, G. Cabibbo, G. Cirrincione, R. Pirrone, C. Cammà Palermo, Amiens (France)

16. Deep Learning for Automated Classification of Liver Tumours on Digitalized Liver Biopsies: An Unsupervised and Semi-Supervised Approach

C. Celsa, A. Sparacino, S. Contino, A. Quattrocchi, T. Halimi, S. Messaoudi, L. Cruciata, G. Cabibbo, R. Pirrone, V. Calvaruso, A. Fagiolini, G. Cirrincione, D. Cabibi, C. Cammà Palermo, Amiens (France)

17. Alcohol Use and Communication Gaps in Autoimmune Liver Diseases: Insights from an Online Patient Survey

M. Delle Monache, V. Ramundo, M. Delle Monache, C. Conigliani, F. Pascucci Rome

18. Predicting The Best Potential Treatment By Artificial Intelligence For Patients Affected By Hepatocellular Carcinoma: Development Of An "augmented" multidisciplinary board.

S. Famularo, O. Cicerone, F. Milana, A. Vitale, M. Maestri, F. Ardito, U. Cillo, F. Giuliani, G. Torzilli, F. Trevisani, E. Giannini Rome, Pavia, Rozzano (MI), Padua, Bologna, Genoa

19. Prospective comparison of Viscoelastic Coagulation Monitor (VCM) and Rotational Thromboelastometry (ROTEM) in the assessment coagulation of cirrhosis

E. Pinto, F. Gerli, C. Bulato, E. Campello, K. Ferdinande, A. Ferrarese, M. Gambato, G. Germani, F. P. Russo, P. Burra, P. Simioni, M. Senzolo, A. Zanetto
Padua

20. Predicting Decompensation in Advanced HCC on Immunotherapy: The ARTE Score

L. Canova, E. Alimenti, L. Argiento, F. Tovoli, G. Cabibbo, F. Marra, C. Vivaldi, A. Dalbeni, F.R. Ponziani, A. Palloni, S. Lonardi, L. Rimassa, L. Lani, P. Federico, G. Svegliati-Baroni, L. Ielasi, C. Mazzarelli, S. De Lorenzo, R. Sacco, P. Toniutto, M. Iavarone
Milan, Bologna, Palermo, Florence, Pisa, Verona, Rome

21. Dynamics of thrombin generation predict thrombo-hemorrhagic events in cirrhosis: a prospective cohort study

A. Zanetto, A. Zanetto, R.A.L. Willems, E. Campello, J. Konings, C. Bulato, M. Kramer,

M. Roest, F.P. Russo, M. Senzolo, P. Burra, H. ten Cate, J. de Vos-Geleen, B. de Laat, P. Simioni
Padua, Maastricht (The Netherlands), Mainz (Germany)


22. Physical frailty is the most important predictor of early mortality in hospitalized patients with decompensated cirrhosis

F. D'Arcangelo, L. M. Vivian, A. Ferrarese, M. Gambato, G. Germani, M. Senzolo, F. P. Russo, P. Burra, A. Zanetto
Padua

23. Porto-sinusoidal vascular disorder and sinusoidal obstructive syndrome in patients treated with thiopurines: a systematic review

E.N. Lynch, A. Curto, M. Tanturli, R. G. Iamello, E. Monaco, M. Vanni, T. Mello, T. Innocenti, G. Dragoni, A. Galli
Florence

24. Long-term real-life experience of semaglutide in a monocentric cohort with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD)



58th AISF ANNUAL MEETING

SESSIONE POSTER - MARCH 19th, 2026

G. Petralli, A. Salvati, S. Cappelli, L. Surace,
L. De Rosa, F. Damone, D. Tricò, A. Solini,
M.R. Brunetto Pisa

25. EUS-guided direct portal pressure, clinically significant portal hypertension and spleen stiffness: diagnostic and prognostic integration in a prospective cohort

F. Martini, L. Salvi, M. Dalla Bella, A. Alessandrini,
D. Balducci, M. Montori, L. Maroni, M. Marzioni,
A. Benedetti, G. Tarantino
Ancona

26. Brief Alcohol Counseling in Steatotic Liver Disease: A Single-Center Observational Study of Six-Month Changes in Alcohol Use, Noninvasive Liver Metrics, and Quality of Life

E. N. Lynch, A. Curto, G. Bianchi, M. Tanturli,
R.G. Iamello, E. Monaco, M. Vanni, T. Mello,
T. Innocenti, G. Dragoni, A. Galli
Florence

27. A Comparative Outcome and Safety Analysis of Lenvatinib Versus Sorafenib in Hepatocellular Carcinoma recurring after Liver Transplantation

M. Sagasta, E. Alimenti, C. Mazzarelli,
M. De Giorgio, F. Villa, C. Dibenedetto,
D. Costantino, F. Tosi, M. Orlando, L. Cesarini,
S. Fagioli, M. Iavarone, P. Lampertico
Milan, Bergamo

28. Progressive decline of HBcrAg levels in patients with chronic hepatitis delta long-term treated with bulevirtide monotherapy

E. Degaspero, F. Facchetti, D. Sambarino,
. Scholtes, B. Testoni, S. Uceda Renteria,
M.P. Anolli, C. Charre, M. L. Plissonnier, R. Perbellini,
A. Callegaro, M. Levrero, F. Zoulim, P. Lampertico
Milan, Lyon (France), Paris (France)

29. The effectiveness and safety of bulevirtide monotherapy are similar in chronic hepatitis delta patients with and without cirrhosis: results from the prospective multicenter d-shield study

M.P. Anolli, E. Degaspero, G. D'Offizzi, A. Rianda,
A. Loglio, M. Viganò, A. Ciancio, Y. Troshina,
M.R. Brunetto, B. Coco, S. Zaltron, A. Cambianica,
M. Milella, E. Rosselli Del Turco, L. Turco, L. Sarmati,
M. Tamè, P. Toniutto, A. Gasbarrini, L. Marinaro,
F. P. Russo, A. Gori, I. Maida, A. Federico,

58th AISF ANNUAL MEETING


SESSIONE POSTER - MARCH 19th, 2026

T.A. Santantonio, R. Bruno, E. G. Giannini, I. Cacciola, F. Morisco, A. Mangia, S. De Nicola, A. Romano, M. Maracci, B. Pinchera, S. L. Crocè, F. Pileri, R. Zampino, M. Persico, P. Pozzoni, A. Pan, A. Pellicelli, N. Coppola, M. Tonnini, E. Grassi, A. Soria, P. Caraceni, G. Svegliati Baroni, I. Arena, V. Esposito, P. Vitiello, M. Puoti, P. Lampertico
Milan, Rome, Bergamo, Turin, Pisa, Brescia, Bari, Bologna, Udine, Padua, Sassari, Naples, Foggia, Pavia, Genoa, Messina, San Giovanni Rotondo (FG), Rozzano (MI), Ancona, Trieste, Modena, Baronissi (SA), Lecco, Cremona, Varese, Monza, Rho (MI)

30. Long-term virological and clinical outcomes in patients with hcv-related cirrhosis treated with bulevirtide monotherapy for up to 4 years (Save-D Study)

E. Degaspero, M. P. Anolli, D. Sambarino, M. Borghi, R. Perbellini, L. Gheorghe, M. Chitul, C. Schramm, H. Schmidt, M. Jachs, T. Reiberger, I. Carey, K. Agarwal, M. Buti, A. Palom, J. Vienneau, M. Tang, G. D'Offizi, F. di Maria, C. Zöllner, F. Tacke, C. Dietz-Fricke, H. Wedemeyer, M. Papatheodoridis, G. Papatheodoridis, F. Van Bömmel, S. Lens, M.R. Brunetto, M. Cardoso, A. Federico,

E. Rosselli Del Turco, M. Meszaros, A. Ciano, Á. Giráldez-Gallego, F. Zoulim, S. Aleman, N. Semmo, S. Metiver, A. Mangia, M. N. Hilleret, U. Merle, M. Viganò, T. A. Santantonio, N. Coppola, A. Pellicelli, J. Foucher, B. Roche, X. Causse, L. D'Alteroche, J. Dumortier, N. Ganne, F. Heluwaert, I. Ollivier, D. Roulot, I. Rosa, F. Pilleri, M. Maracci, M. Tonnini, J. P. Arpurt, K. Barange, E. Billaud, S. Pol, A. Gervais, A. Minello, M. Puoti, P. Lampertico - Milan, Bucharest (Romania), Essen (Germany), Vienna (Austria), London (UK), Barcelona (Spain), Calgary (Canada), Rome, Berlin (Germany), Hannover (Germany), Athens (Greece), Leipzig (Germany), Pisa, Amadora (Portugal), Naples, Bologna, Montpellier (France), Turin, Sevilla (Spain), Lyon (France), Stockholm (Sweden), Bern (Switzerland), Toulouse (France), San Giovanni Rotondo (FG), Grenoble (France), Heidelberg (Germany), Bergamo, Foggia, Bordeaux (France), Villejuif (France), Tours (France), Bobigny (France), Annecy (France), Caen (France), Créteil (France), Modena, Ancona, Avignon (France), Toulouse (France), Nantes (France), Paris (France), Dijon (France)



58th AISF ANNUAL MEETING

SESSIONE POSTER - MARCH 19th, 2026

31. Systemic inflammatory markers predict overall survival and therapeutic response in immunotherapy-treated hepatocellular carcinoma

A. Rocco, C. Sgamato, F. Giordano, D. Angrisani, M. R. Attanasio, M. Guarracino, R. Tortora, G.G. Di Costanzo
Naples

32. Improvement in 3 noninvasive tests through 144 weeks of bulevirtide monotherapy in patients with chronic hepatitis delta with and without virologic response

M. Brunetto, S. Aleman, P. Andreone, P. Bogomolov, V. Chulanov, N. Geyvandova, V. Morozov, O. Sagalova, T. Stepanova, A. Lichtman, R.C. Mercier, D. Manuilov, M. Li, J. Schulze zur Wiesch, S. Zeuzem, H. Wedemeyer, P. Lampertico
Pisa, Stockholm (Sweden), Modena, Moscow (Russian Federation), Stavropol (Russian Federation), Samara (Russian Federation), Chelyabinsk (Russian Federation), Foster City (USA), Hamburg (Germany), Frankfurt am Main (Germany), Hannover (Germany), Milan

33. Viral Dynamics After Achieving Undetectable HDV RNA With Bulevirtide Monotherapy in Study MYR301

P. Lampertico, S. Aleman, M. Brunetto, P. Bogolomov, V. Chulanov, T. Stepanova, A. Lichtman, D. Manuilov, Z. Wang, M. Cornberg, S. Zeuzem, H. Wedemeyer
Milan, Stockholm (Sweden), Pisa, Moscow (Russian Federation), Foster City (USA), Hannover (Germany), Frankfurt (Germany)

34. Multidisciplinary Follow-up after Liver Transplantation: Diagnostic Yield and Impact on Cancer and Cardiovascular Outcomes

E.N. Lynch, A. Curto, M. Tanturli, R. G. Iamello, G. Lubian, E. Monaco, M. Vanni, T. Mello, T. Innocenti, G. Dragoni, S. Gitto, A. Galli
Florence

35. Early Protein C Pathway in Porto-Sinusoidal Vascular Disorder: A Potential Marker of Porto Sinusoidal Endothelial Dysfunction

K. Ferdinande, A. Zanetto, C. Bulato, E. Campello, S. Gavasso, E. Pinto, P. Simioni, M. Senzolo
Padua

36. Albumin as a predictor of long-term post-TIPS survival

C.B. Molteni, M. Lucà, G. Tosetti, C. Cicalini, M. Primignani, L. Argiento, S. Stella, P. Lampertico
Milan

37. TIPS for Refractory Ascites Ameliorates Trajectories, and Non-Acute Decompensation Status Favors Recompensation

K. Ferdinande, A. Zanetto, S. Groff, G. Barbiero, M. Battistel, C. Michele, A. Ferrarese, E. Pinto, G. Germani, M. Gambato, F. P. Russo, P. Burra, M. Senzolo
Padua

38. Predictors of hepatic encephalopathy after TIPS: a single-center retrospective analysis

C. Cicalini, M. Lucà, L. Argiento, G. Tosetti, C.B. Molteni, S. Stella, P. Lampertico
Milan

39. The high genetic variability of HDV sub-genotypes 1 can drive the selection of divergent genetic pathways modulating HDV replicative potential and cytolytic activity

L. Piermatteo, A. Magnapera, G. Torre, L. Carioti,


S. D'Anna, L. Etogo, A. Bertoli, P. Paba, A. Olivero, E. Teti, A. Di Lorenzo, V. Malagnino, M. Iannetta, L. Baiocchi, S. Francioso, I. Lenci, U. Cillo, A. Vitale, G. Brancaccio, G.B. Gaeta, A. Ciancio, F. Ceccherini Silberstein, S. Grelli, L. Sarmati, M. Rizzetto, G.P. Caviglia, R. Salpini, V. Svicher
Rome, Turin, Padua, Naples

40. Global ROTEM (G-ROTEM) profile predicts major bleeding in patients with Acute-on-Chronic Liver Failure

E. Pinto, A. Zanetto, C. Bulato, E. Campello, K. Ferdinande, A. Ferrarese, M. Gambato, G. Germani, F.P. Russo, P. Burra, P. Simioni, M. Senzolo
Padua

41. Mapping Somatic Evolution in Steatotic Liver Disease through Integrated Tissue and Organoid Genomics

A. Cherubini, S. Mira, V. Moretti, H.E. Torgabehei, E. Casirati, L. Cerami, G. Periti, F. Malvestiti, S. Pelusi, D. Dondossola, D. Prati, L. Ronzoni, L. Valenti
Milan



58th AISF ANNUAL MEETING

SESSIONE POSTER - MARCH 19th, 2026

42. Metabolic ferroptosis as targetable signature for the genetic subtype of MASLD

E. Paolini, M. Meroni, M. Longo, S. Badiali, M. Maggioni, A. L. Fracanzani, P. Dongiovanni
Milan

43. PreDEA Study, Prevention in Emergency Departments: the case of hepatic steatosis

V. D'Arpino, A. Fontana, A. Cirella, G. Sinatti, V. Caputo, S. J. Santini, C. Balsano
L'Aquila

44. Circulating reticulated platelets in hepatocellular carcinoma with and without liver cirrhosis

P. Guerra, S. Toffanin, C. Bulato, A. Bonato, S. Cagnin, C. Soldà, M. D. Rizzato, S. Lonardi, F. Bergamo, A. Zanetto, E. Pinto, M. Senzolo, S. Montagnese, P. Simioni, E. Campello, A. Martini
Padua

45. Longitudinal evaluation of neutrophil-to-lymphocyte ratio (NLR) as a prognostic biomarker in patients with hepatocellular carcinoma (HCC) treated with atezolizumab-bevacizumab.

S. Ascari, F. Tovoli, E. Barchetti, A. Granito, B. Stefanini, F. Ravaioli, L. Braccischi, F. Piscaglia
Bologna

46. Intra-hepatic HDV activity can be sustained by HBsAg deriving from HBV-DNA integration and can modulate virological response to bulevirtide

S. D'Anna, I. Grossi, L. Piermatteo, A. Di Lorenzo, L. Carioti, G. Brancaccio, E. Teti, G. Torre, C. Tramontozzi, V. Malagnino, M. Iannetta, C. Pasquazzi, U. Cillo, A. Vitale, E. Gringeri, M.A. Magrofuoco, L. Baiocchi, S. Francioso, I. Lenci, A.M. Geretti, M. L. Abate, A. Olivero, G.B. Gaeta, L. Sarmati, M. Rizzetto, G. . Caviglia, V. Svicher, R. Salpini
Rome, Padua, Turin, Naples

47. Does Seronegative Autoimmune Hepatitis really exist?

F. Colapietro, C. D. Slooter, K. Zachou, D. di Zeo Sánchez, M. Robles-Díaz, M. García-Cortés, S. Santopietro, V. Ronca, A. Gerussi, P. Invernizzi, R. J. Andrade, G.N. Dalekos, J. P. H. Drenth, Y. de Boer, A. Lleo
Pieve Emanuele (MI), Milan, Amsterdam (The

Netherlands), Larissa (Greece), Málaga (Spain), Madrid (Spain), Monza

48. Distinct HBsAg isoform patterns reflect viral activity and disease stage in chronic HDV infection

I. Grossi, C. Tramontozzi, A. Magnapera, S. D'Anna, E. Dileo, A. Olivero, L. Piermatteo, G. Mengozzi, A. Ciancio, A. Loglio, M. Viganò, S. Fagiuoli, P. Colombatto, B. Coco, M.R. Brunetto, D. Angrisani, A.G. Lanza, C. Magni, A. Gori, V. Messina, M. Milella, A. Saracino, L. Marinaro, G. Cariti, V. Cossiga, F. Morisco, S. Cretella, G. Verucchi, E. Biliotti, G. D'Offizi, M. Feasi, E. Pontani, C. Coppola, R. Rapetti, M. Pirisi, A. Izzi, T. Santantonio, V. Di Marco, A. Marrone, N. Coppola, M. Rizzi, A.M. Cattelan, G.A. Niro, P. Toniutto, F.R. Ponziani, L.S. Belli, A. Federico, G. Bertino, M. Barone, M. Puoti, A. Civolani, M. Distefano, L. A. Surace, R. Cozzolongo, E.M. Cella, E. Teti, P. Lampertico, T. Stroffolini, R. Salpini, V. Svicher, M. Rizzetto, G. P. Caviglia
Rome, Turin, Bergamo, Milan, Pisa, Naples, Caserta, Bari, Bologna, Genoa, Gragnano (NA), Novara, Foggia, Palermo, Bergamo, Padua, San Giovanni Rotondo (FG), Udine, Catania, Bari, Cagliari, Siracusa, Lamezia Terme (CZ), Castellana Grotte (BA)

49. Hepatoprotective effects of Momordica charantia extracts in in vitro models of MASLD

D. Gabbia, I. Zanutto, A. Signor, S. Pettenuzzo, M. Colognesi, M. Roverso, S. Bogialli, S. De Martin
Padua

50. The impact of CFTR genotype on liver impairment in patients with cystic fibrosis


V. Cossiga, M. Capasso, E. Pellegrino, P. Iacotucci, S. Albano, L. Ferrillo, F. Mazzitelli, J. Somma, L. Ranieri, M. Guarino, V. Carnovale, F. Morisco
Naples

51. α -KG–Driven Immune Escape in Hypoxic MASLD-HCC: Amino Acid Metabolism at the Crossroads

B. Foglia, J. Nurcis, S. Sutti, G. Caviglia, C. Bocca, P. Carucci, S. Gaia, R. Romagnoli, E. Bugianesi, M. Parola, S. Cannito - Novara, Turin

52. Multidisciplinary clinic approach improves immunotherapy treatment outcomes in unresectable hepatocellular carcinoma: a multicentre retrospective study

A. Auriemma, M. Vicardi, M. E. Bellucco, C. Mazzarelli, F. Villa, G. Dispinzieri, L.A. Natola,



58th AISF ANNUAL MEETING

SESSIONE POSTER - MARCH 19th, 2026

C. Soldà, S. Lonardi, L. Foltran, S. Torresan, S. Rota, T. Pressiani, L. Rimassa, D. Sacerdoti, M. Milella
Verona, Milan, Padua, Aviano (PN), Rozzano (MI),
Pieve Emanuele (MI)

53. Statins in Cirrhosis and Its Complications: An Umbrella Review and Meta-Analysis of Systematic Reviews

A. Dalbeni, F. Cattazzo, M. Vicardi, L. A. Natola,
V. Di Maria, D. Sacerdoti, F. Cinque, R. Lombardi
Verona, Milan

54. Changing Epidemiology and Clinical Presentation of Hepatic Cirrhosis: Data from the SORPRESA Cohort Study

T. Sarcina, M. Masarone, E. Errigo, P. Angeli,
S. Incicco, F.R. Ponziani, L. Stella, G.G. Di Costanzo,
D. Angrisani, A. Federico, M. Diallo, A. Pasta,
G. Federici, E. Pompili, P. Torre, F. Morisco,
L. Ranieri, N. Coppola, M. Stanzione, A. Aghemo,
S. De Nicola, E. G. Giannini, V. Di Marco, M. Persico
Salerno, Palermo, Padua, Rome, Naples, Genoa,
Bologna, Rozzano (MI)

55. The interplay of epigenetic and redox biomarkers in a mouse model of metabolic dysfunction-associated steatotic liver disease

M.R. Braghini, G. Andolina, F. Tiano, N. Panera,
A. Pastore, C. De Stefanis, G. Di Giovamberardino,
M. Pezzullo, A. Mosca, C. Balsano, A. Mangia,
L. Miele, A. Alisi
Rome, L'Aquila, San Giovanni Rotondo (FG)

56. Impact of PNPLA3 p.I148M variant on qFibrosis-based liver fibrosis features in MASLD biopsies in the Milan Biobank cohort

G. Periti, K. Akbary, F. Malvestiti, M. Maggioni,
S. Margarita, J. Rondena, L. Ronzoni, R. D'Ambrosio,
D. Dondossola, A. Cherubini, S. Pelusi, D. Prati,
D. Tai, L. Valenti
Milan, Singapore

57. Impact of pre-treatment serum albumin concentration on clinical outcomes in patients with cirrhosis and ascites receiving long-term albumin

E. Pompili, G. Zaccherini, S. Nardelli, S. Piano,
C. Alessandria, S. Neri, F. G. Foschi, F. Levantesi,
A. Airolidi, L. Simone, G. Svegliati-Baroni, S. Fagiuoli,
F. Marra, R. Cozzolongo, G. Iannone, M. Biselli,

O. Riggio, P. Angeli, M. Bernardi, M. Baldassarre, P. Caraceni
Bologna, Rome, Italy, Padua, Turin, Catania, Faenza (RA), Milan, Ferrara, Ancona, Bergamo, Florence, Castellana Grotte (BA)

58. SORPRESA-HCC: A Multicenter Study on the Changing Epidemiology of HCC in Cirrhosis

T. Sarcina, P. Torre, C. Celsa, P. Angeli, F.R. Ponziani, A. Liguori, G. G. Di Costanzo, D. Angrisani, A. Federico, M. Romeo, A. Pasta, G. Iannone, G. Zaccherini, M. Masarone, F. Morisco, V. Cossiga, N. Coppola, G. Stornaiolo, A. Aghemo, S. De Nicola, V. Di Marco, E. G. Giannini, M. Persico
Salerno,


59. HCC incidence and risk stratification in patients with metabolic dysfunction-associated steatotic liver disease on long-term follow-up: a retrospective multicentre study

G.P. Caviglia, M. Guariglia, R. D'Ambrosio, R. Perbellini, P. Lampertico, F. Damone, G. Petralli, M. R. Brunetto, S. Pelusi, L. Valenti, A. Liguori, M. Pompili, L. Miele, A. Armandi, J.M. Schattenberg, F. Barutta, G. Gruden,

E. Shahini, G. Giannelli, M. Dallio, A. Federico, G. Pennisi, S. Petta, M. Pirisi, F. Salomone, M. Sangineto, G. Serviddio, E. Bugianesi
Turin, Milan, Pisa, Rome, Mainz (Germany), Homburg (Germany), Castellana Grotte (BA), Naples, Palermo, Novara, Catania, Foggia

60. Unsupervised Machine Learning Reveals Distinct Quality-of-Life Clusters Across Autoimmune Liver Diseases

E. Merelli, D. Verda, A. Piazza, N. Uhlenbusch, R.J. A.L.M. Snijders, B. Löwe, A.W. Lohse, A. Braun, M. K. Janik, P. Milkiewicz, P. Kovats, M. Papp, B. Balogh, F. Bolis, L. Cristoferi, M. Carbone, P. Invernizzi, L. Aamann, H. Ytting, J. Madaleno, B. Canhão, E.T.T.L. Tjwa, J.P.H. Drenth, L. Grønbaek, H. Grønbaek, V. Ronca, K. Olsen, Y.H. Oo, A.J. van der Meer, B. Engel, A. Campos-Murguia, R. Taubert, Ö.M. Koc, M. Kramer, T.J. Gevers, C. Schramm, A. Gerussi
Monza, Genoa, Hamburg (Germany), Nijmegen (The Netherlands), Warsaw (Poland), Szczecin (Poland), Debrecen (Hungary), Milan, Copenhagen (Denmark), Coimbra (Portugal), Maastricht (The Netherlands), Aarhus (Denmark),



58th AISF ANNUAL MEETING

SESSIONE POSTER - MARCH 19th, 2026

Horsens (Denmark), Birmingham (UK), Rotterdam (The Netherlands), Hannover (Germany)

61. Unraveling GLUT3-Mediated Metabolic and Immune Modulation in Intrahepatic Cholangiocarcinoma through Multi-Omics Analysis

M. A. Polidoro, B. Franceschini, F. Milana, C. Soldani, L. Lambroia, R. Carriero, L. Evangelista, A. Aghemo, A. Aghemo, M. Donadon, M. Donadon, G. Torzilli, G. Torzilli, A. Lleo, A. Lleo
Rozzano (MI), Pieve Emanuele (MI), Novara

62. Gene expression dynamics of immune cells and its genetic determinants in primary sclerosing cholangitis

C. Caime, P. Demela, R. Asselta, P. Invernizzi, A. Gerussi, B. Soskic
Milan

63. Functional and molecular profiling of primary intrahepatic cholangiocarcinoma cell lines along its tissue histo-morphological spectrum

M. Franchitto, G. Carpino, D. Overi, S. Paradiso, T. De Luca, F. Belardinilli, G. Giannini, F. Razionale, F. Ardito, A. M. De Rose, F. Giuliani, E. Gaudio,

D. Alvaro, V. Cardinale
Rome, Boston (USA)

64. Sustained and Clinically Meaningful Improvements in Moderate to Severe Pruritus Patients With Primary Biliary Cholangitis Treated With Seladelpar: Results From the ASSURE Study up to 30 Months

G. M. Hirschfield, A. E. Kremer, C. Levy, K.V. Kowdley, H. Elbeshbesy, J. Heo, F. Frigerio, K.M. Kwon, J. Liu, C. Burk, D.B. Crittenden, M.J. Mayo
Toronto (Canada), Zürich (Switzerland), Miami (USA), Seattle (USA), St. Louis (USA), Busan (Republic of Korea), Milan, Foster City (USA), Dallas (USA)

65. Management of Primary Biliary Cholangitis in Italian Clinical Practice: Insights from a Retrospective Observational Real-World Analysis

V. Perrone, S. Mazzoni, F. Frigerio, L. Giannessi, L. Degli Esposti
Bologna, Milan

66. Disease Control as Evidenced by Longitudinal Transient Elastography Measurements in the

ASSURE Study: 36 Months of Treatment With Seladelpar Is Associated With Stable or Improved Liver Stiffness in Patients With Primary Biliary Cholangitis

C.L. Bowlus, G.M. Hirschfield, A.M. Villamil, K.V. Kowdley, H. Elbeshbeshy, C. Corpechot, A.E. Kremer, P.J. Trivedi, Y. Kallis, S. H. Jeong, F. Frigerio, K.M. Kwon, V. de Ledingen, X. Qi, D.B. Crittenden, C. Levy
Sacramento (USA), Toronto (Canada), Buenos Aires (Argentina), Seattle (USA) St. Louis (USA), Paris (France), Zürich (Switzerland), Birmingham (UK), London (UK), Seongnam (South Korea), Milan, Foster City (USA), Miami (USA)

67. BAG3 as a Fibrosis-Associated Biomarker in MASLD: Integration with PNPLA3 and TM6SF2 Genetic Risk

B.M. Motta, M. Festa, A. Rosati, A. Basile, T. Sarcina, M.C. Turco, M. Persico
Salerno, Baronissi (SA)

68. Seladelpar Is Associated With a Sustained Reduction in Cholestatic Markers and a Consistent Safety Profile in Patients With Primary Biliary


Cholangitis Treated up to 48 Months in the Ongoing, Open-Label ASSURE Study

D. Pratt, E. J. Lawitz, C. L. Bowlus, F. Frigerio, K.M. Kwon, S. Proehl, X. Qi, R. P. Kustra, A.M. Villamil
Boston (USA), San Antonio (USA), Sacramento (USA), Milan, Foster City (USA), Buenos Aires (Argentina)

69. Impact of malnutrition and sarcopenia on survival in HCC treated with immune-based systemic therapy

L. Argiento, L. Canova, E. Alimenti, L. I. Belli, S. Rocchetto, M. Platì, F. Cicchetti, E. Xhepa, P. Biondetti, M. Bruccoleri, M. Iavarone, P. Lampertico
Milan

70. PSC-DM: development and validation of a clinical diagnostic model for distinguishing primary from secondary sclerosing cholangitis
M. Scaravaglio, R. V. Motta, L. Cristoferi, C. Maino, A. Marini, E. Nofit, E. Pesatori, C. Gallo, F. Bolis, D. D'Amato, A. Curto, F. Malinverno, A. Gerussi, R. Viganò, M. Viganò, S.J. Rossi, K. V. Kowdley, P. Invernizzi, A. Nardi, M. Carbone, E. L. Culver



58th AISF ANNUAL MEETING SESSIONE POSTER - MARCH 19th, 2026

Milan, Oxford (UK), Monza, Bergamo, Florence,
Greenwood Village (USA), Seattle (USA), Rome

71. Steatosis speaks to the heart: early left ventricular global longitudinal strain impairment in metabolic dysfunction-associated steatotic liver disease

C. Giglio, E. Lodi, B. Lei, A. Colecchia, L. Carulli
Modena

72. HCV screening and linkage to care in the 1969-1989 birth-cohort population: the Bergamo experience

L. Dell'Oro, A. Loglio, L. Rota, L. Ongis, D. Isabella,
L. Pasulo, G. Bombardieri, M. G. E. Arosio, S.
Faggioli
Milan, Bergamo

73. Exploring the hepatoprotective potential of psilocybin microdosing in steatohepatitis: in vitro and in vivo studies

A. Signor, M. Colognesi, D. Gabbia, A. Mattarei,
S. Comai, G. Pasut, F. Folli, P. L. Manfredi
Padua, Milan, Kerhonkson (USA)

74. Multidisciplinary management of adult patients with Fontan Associated Liver Disease

G. Tomauiuolo, M. Saracco, S. Strona, C. Manuli,
R. Lasco, M. H. Falzone, R. Gastaldi, E. Gribaudo,
G. Annoni, F. Ferroni, C. P. Napoleone, M. Boffini,
M. Rinaldi, R. Romagnoli, S. Martini
Turin

75. Spatial Proteomics Uncovers Region-Specific Proteomic Signatures in Autoimmune Liver Diseases

E. Merelli, V. Denti, G. Capitoli, C. Caime,
G. Cazzaniga, M. Cadamuro, F. Malinverno,
L. Cristoferi, A. Smith, F. Pagni, P. Invernizzi,
F. Magni, I. Piga, V. L'Imperio, M. Carbone,
A. Gerussi
Monza, Milan

76. Prospective evaluation of the effects of GLP1 receptor agonists and SGLT2 inhibitors in MASLD patients with type 2 diabetes

A. Mega, C. Turri, F. Vittadello, L. Marzi, R. Sacco,
C. Stasi, M. Zöschg, E. Lorefice, A. Floreani
Bolzano, Padua, Foggia, Rome, Empoli (FI), Padua,
Negrar (VE)

77. Predictors of clinical course in patients surviving an acute decompensation of cirrhosis

C. Gambino, A. Accetta, E. Pompili, R. Filomia, C. Passalacqua, G. Iannone, C. Pitrone, G. Fusco, C. Asero, G. La Manna, G. Zaccherini, I. Cacciola, G. Squadrito, P. Caraceni, P. Angeli, S. Piano
Padua, Bologna, Messina

78. ELF score and its components predict clinical outcomes after TIPS


L. Lani, M. Hintersteiner, T. Müllner-Bucsics, S. Riegler, G. Kramer, C. Sebesta, P. Thöne, B. Simbrunner, L. Reider, M. Weiss-Tessbach, R. Marculescu, M. Schoder, M. Trauner, M. Mandorfer, T. Reiberger, L. Hartl
Bologna, Vienna (Austria)

79. Quality of life during Transition after Liver Transplantation

F. Leonardi, A. Merisio, P. Stroppa, L. Pasulo, M. Triolo, F. Ideo, V. Casotti, D. Pinelli, M. S. Spada, L. D'Antiga, S. Fagioli
Bergamo

80. HBsAg trajectories might predict virological outcomes in patients with chronic hepatitis B infection

S. Battistella, A. Roca, A. Pocurull, Z. Marino, S. Rodriguez-Tajes, X. Forns, S. Lens
Padua, Barcelona (Spain)



58th AISF ANNUAL MEETING

SESSIONE POSTER - MARCH 20th, 2026

1. Two-tier screening approach for liver fibrosis stratification in outpatients with type 2 diabetes mellitus: A multicenter cross-sectional study

A. Mantovani, R. Lombardi, A. Dalbeni, R. Morandin, M. G. Lando, V. Fiorio, N. Rolli, M. Forti, D. Messetti, M. Zoncapè, I. Milani, M. E. Parrotta, D. Capoccia, V. Guglielmi, F. Leonetti, P. Sbraccia, A.L. Fracanzani, G. Targher - Verona, Milan, Latina, Rome

2. GAAD score as a diagnostic and prognostic marker from cirrhosis to hepatocellular carcinoma

S. Cagnin, A. Aita, A. Biasiolo, G. Tretti, S. Quarta, A. Stefani, M. Ruvoletto, P. Guerra, R. Donghia, G.

3. The evolving landscape of TIPS. From traditional indications to everyday clinical practice

Y. Capraro, L. Lamfu, R. Argirò, D. Morosetti, I. Lenci, M. Milana, L. Baiocchi
Rome

4. Blood Metabolomic Signature for Diagnosing Cirrhosis and Predicting Prognosis in Patients with Primary Sclerosing Cholangitis

E. Catanzaro, A. Lapitz, P. Milkiewicz, M. Elgozair, F. Ahmed, J.R. Hov, T. Folseraas, M. Carbone,

R.I.R. Macias, C. Schramm, C. Alonso, M. Milkiewicz, L. Izquierdo-Sánchez, A. La Casta, R. Jimenez-Aguero, M. J. Perugorria, L. Cristoferi, M. Arrese, J. Chahuan, J. Bustamante, M. Dill, S. Rossi, M. Walmsley, L. Bujanda, L. Roberts, T.H. Karlsen, L. Fabris, N. Cazzagon, P.M. Rodrigues, J. M. Banales
Padua, San Sebastian (Spain), Warsaw (Poland), Rochester (USA), Oslo (Norway), Milan, Salamanca (Spain), Hamburg (Germany), Derio (Spain), Szczecin (Poland), Monza, Santiago (Chile), Barakaldo (Spain), Heidelberg (Germany), Denver (USA), Manchester (UK)

5. Long-term outcomes of patients with Porto-Sinusoidal Vascular Disorder, with or without portal hypertension features

E. Farina, A. Loglio, G. Colloredo, A. Sonzogni, . Cerini, C. Severgnini, L. Licini, P. Tebaldi, P. Marra, A. Gianatti, S. Fagioli, M. Viganò - Bergamo, Milan, Ponte San Pietro (BG), Seriate (BG), Milan

6. Real-life evaluation of the FIB-4 two-step fibrosis screening algorithm in MASLD: measurement of waist circumference might make the difference

*R. Lombardi, F. Cinque, A. Cespiati, F. Alletto,
D. Smith, G. Oberti, E. Fatta, E. Pulixi, G. Maffi,
A. Mantovani, A. Dalbeni, A. L. Fracanzani*
Milan, Verona

7. Lysosomal acid lipase (LAL) activity is inversely associated with histological progression of metabolic dysfunction-associated steatotic liver disease (MASLD): a single-centre prospective study

*R. Lombardi, F. Cinque, A. Cespiati, C. Bertelli,
G. Pisano, G. Oberti, J. Currà, E. Calzavara,
F. Alletto, C. Garavaglia, G. Cincotto,
M. Gomaraschi, A. L. Fracanzani*
Milan

8. Long-term albumin treatment improves outcomes in patients with cirrhosis and ascites

*V. Santori, M. Tonon, N. Torp, E. Pompili, L. Balcar,
C. Lobel, R. Gagliardi, J. Embacher, M. Israelsen,
A. Accetta, S. Johansen, L. Hafner, M. Trauner,
M. Mandorfer, T. Reiberger, A. Krag, P. Caraceni,
P. Angeli, S. Piano, G. Semmler*
Padua, Odense (Denmark), Bologna, Vienna (Austria)

9. Reprogramming of tumour-associated macrophages in liver affected by colorectal cancer metastases


*C. Cives-Losada, C. Soldani, B. Franceschini,
M.A. Polidoro, A. Gazzillo, A. Cammarota, F. Milana,
F. Clemente, A. Anselmo, L. Di Tommaso, G. Torzilli,
M. Donadon, A. Lleo*
Novara, Rozzano (MI), Milan, Pieve Emanuele (MI)

10. Lower resilience and perceived social support in pbc patients: fatigue as a major determinant of psychological adaptation

*C. Sgamato, R. Clavo, L. Pisciotta, P. De Crescenzo,
L. Romano, A. Torriero, P. Coccoli, G. Nardone,
A. Rocco - Naples*

11. LiverCARD: opportunistic Cardiovascular Risk assessment in MASLD using a multimodal AI pipeline

*P. Bruno, A. Quarta, E. De Rose, V. Caputo,
S.J. Santini, G. Greco, P. Palumbo, S. Germano,
M. Vinci, F. Calimeri, E. Di Cesare, A. Guzzo,
C. Balsano*
Rende (CS), L'Aquila, Rome



58th AISF ANNUAL MEETING

SESSIONE POSTER - MARCH 20th, 2026

12. Portal Hypertension: multiple treatment to reach the goal

S. S. Sciarrone, M. Arena, G. Iabichino, M. Di Leo, L. Fini, A. Losco, S. Zatelli, D. Viganò, G. Tagliamonte, A. Murru, L. De Luca
Milan

13. MASLD and Mental Health: association of the liver disease with anxiety, depression and binge eating

S. De Nicola, A. Bertazzoni, A. Catena, N. Pugliese, C. Masetti, V. Ronca, B. Mazzuccato, A. Lleo, M. Cucchi, A. Aghemo
Rozzano (MI), Pieve Emanuele (MI)

14. PSVD: specific histological features and risk of PVT

M. Lucà, L. Valenti, L. Argiento, C. Cafasso, C. Cicalini, C. B. Molteni, G. Tosetti, M. Primignani, S. Stella, M. Maggioni, P. Lampertico
Milan

15. Obesity drives mild cognitive impairment in metabolic-associated steatotic liver disease

C. Sgamato, R. Clavo, L. Pisciotta, C. Miele,

A. Torriero, P. Coccoli, G. Nardone, A. Rocco
Naples

16. Diagnostic performance of available biomarkers for Hepatocellular Carcinoma: a comprehensive meta regression analysis

A. Dalbeni, M. Vicardi, L. A. Natola, F. Cattazzo, M. Bevilacqua, L. Dalle Carbonare, D. Sacerdoti
Verona

17. Liver Transplantation for Primary Sclerosing Cholangitis: A 35-Year Single-Center Experience at ASST GOM Niguarda

D. D'Amato, C. Mazzarelli, A. Curto, A. Airoidi, F. Aprile, C. Becchetti, M. Cucco, G. Dispinzieri, G. Perricone, M. Vangeli, F. Bolis, A. Bonfichi, M. Clemente, L. S. Belli, A. Lauterio, R. Viganò, M. Carbone
Milan, Florence

18. Risk factors in Intrahepatic Cholangiocarcinoma a Single-Center Cohort Analysis

D. Costantino, M. De Giorgio, P. Rossi, C. Severgnini, S. Fagioli
Bergamo, Milan

19. A Global Delphi Consensus Involving Patients, Industry, Clinicians, and Regulators on Surrogate Endpoints and Real-World Evidence in Primary Biliary Cholangitis: an EASL-AASLD Framework for Therapeutic Development

M. Scaravaglio, A. Martins, C.L. Bowlus, C.A. Couto, C. Corpechot, B.E. Hansen, G.M. Hirschfield, D.E.J. Jones, M.J. Mayo, A. Villamil, J. Willemse, C. Levy, M. Carbone, A. Lleo
Monza, Miami (USA), Sacramento (USA), Belo Horizonte (Brazil), Paris (France), Rotterdam (The Netherlands), Toronto (Canada), Newcastle (UK), Dallas (USA), Buenos Aires (Argentina), Hoogland (The Netherlands), Milan

20. Glucagon-Like Peptide-1 Receptor Agonists and Hepatocellular Carcinoma prevention: a meta-analysis and clinical decision framework

M. Vicardi, A. Dalbeni, L. A. Natola, F. Cattazzo, A. Auriemma, R. Lombardi, F. Cinque, A. Mantovani, L. Dalle Carbonare, D. Sacerdoti
Verona, Milan


21. Efficacy and Safety of Mycophenolate Mofetil as First and Second line Therapy in Autoimmune Hepatitis: A Retrospective Single-center Analysis according to Azathioprine Exposure and Response

M. Clemente, D. D'Amato, C. Becchetti, F. Berardi, L. S. Belli, M. Carbone, R. Viganò
Milan

22. FiOCA Study: Comparative Transplant-Free Survival in Primary Biliary Cholangitis Patients Receiving Obeticholic Acid or Fibrates.

V. Ronca, A. De Vincentis, A. Tanaka, C. Corpechot, P. Trivedi, F. Terracciani, L. Cristoferi, G. Cancado, M. Scaravaglio, N. Cazzagon, N. Abbas, K. Olsen, S. Rodriguez-Tajes, A. Martins, F. Colapietro, M.C. Londoño, N. Gatselis, V. Lygoura, E. Lytvyak, A. Montano-Loza, A. Gerussi, E. Culver, G. Dalekos, D. D'Amato, A. van der Meer, F. Nevens, E. Zigmond, V. Calvaruso, L. Sierra, R. Barba, A. Bonder, A. Villamil, X. Verhelst, C. Levy, H. Ytting, R. Viganò, M. Viganò, A. Lleo, P. Invernizzi, U. Vespasiani-Gentilucci, G. Hirschfield, B. Hansen, M. Carbone

Pieve Emanuele (MI), Rozzano (MI), Rome, Tokyo (Japan), Paris (France), Birmingham (UK), Belo



58th AISF ANNUAL MEETING

SESSIONE POSTER - MARCH 20th, 2026

Horizonte (Brazil), Padua, Miami (USA), Larissa (Greece), Alberta (Canada), Oxford (UK), Rotterdam (The Netherlands), Leuven (Belgium), Tel Aviv (Israel), Palermo, Boston (USA), Buenos Aires (Argentina), Ghent (Belgium), Copenhagen (Denmark), Milan, Bergamo, Toronto (Canada), Monza

23. Impact of Liver Histology and MASLD-Associated Genetic Variants on Insufficient Weight Loss After Bariatric Surgery

F. Cinque, S. Badiali, M. Meroni, M. Longo, E. Paolini, E. Galfrascoli, G. Oberti, G. Pisano, E. Calzavara, A. Cespiati, L. Boni, P. Dongiovanni, R. Lombardi, A. L. Fracanzani
Milan

24. Clinical Presentation and Determinants of Disease Progression in Cirrhosis: data from the SORPRESA Study Cohort

V. Calvaruso, G. Di Maria, P. Angeli, S. Incicco, F.R. Ponziani, A. Liguori, G.G. Di Costanzo, D. Angrisani, A. Federico, M. Romeo, A. Pasta, P. Caraceni, S. Bighini, M. Masarone, F. Morisco, M. Guarino, N. Coppola, G. Stornaiuolo, A. Aghemo, S. De Nicola, C. Cammà, M. Persico, E.G. Giannini, V. Di Marco

Palermo, Padua, Rome, Naples, Genoa, Bologna, Salerno, Rozzano (MI)

25. Comparison between radiologic pre-liver transplant assessment of the presence and size of HCC and the histological findings obtained in the explanted liver

E. Garlatti Costa, D. Bitetto, E. Fumolo, E. Fornasiere, D. Lorenzin, A. Tullisso, U. Baccarani, P. Toniutto
Udine

26. Real-world experience with Elafibranor in patients with Primary Biliary Cholangitis previously treated with Obeticholic Acid: an Italian Multicenter Observational Study

M. Viganò, D. Montecalvo, S. Labanca, F. Ponziani, E. N. Lynch, M. Distefano, F. Terracciani, M. Cannavò, V. Ronca, L. Cristoferi, A. Gerussi, C. De Benedittis, V. Pace Palitti, L. Napoli, T. Zolfino, G. Alagna, V. Calvaruso, A. Moretti, G. Rizzo, M. Marzioni, N. Cazzagon, E. Lorefice, D. Roccarina, R. Cozzolongo, L. Scribano, G. Vitale, B. Coco, A. Pellicelli, F. Cerini, A. Castellaneta, C. Fabbri, A. Andrealli, A. Garribba, L. Fabris, E. Pesatori,

A. Loglio, A. Grossi, S. Cariatì, L. Stella, M. Russello,
A. Lleo, C. Rigamonti, A. Galli, U. Vespasiani
Gentilucci, D. Alvaro, E. Nofit, S. Fagioli,
M. Carbone, P. Invernizzi, E. G. Giannini
Rome, Genoa, Florence, Siracusa, Catania,
Milan, Monza, Novara, Pescara, Faenza (RA),
Cagliari, Sassari, Palermo, Chieti, Ancona, Padua,
Empoli (FI), Castellana Grotte (BA), Bologna, Pisa,
Bari, Como, Ravenna

27. Minimally invasive hybrid Transjugular and Percutaneous PortoHepatic Pressure Gradient measurement (hTP-PHPG): safety and diagnostic value in patients with undefined or mixed-etiology portal hypertension


D. Saltini, M. Bianchini, A. S. Velasco Mayorga,
T. Guasconi, G. Lo Cascio, A. Piscopo, N. Giglio,
F. Scianò, F. Milosa, R. M. Critelli, A. Colecchia,
F. Schepis
Moden

28. Quantified EEG improves prediction of recurrent overt hepatic encephalopathy after elective TIPS: development and internal validation of a multivariable model

D. Saltini, L. Zarantonello, A. Zanetto, T. Guasconi,
C. Caporali, A. Piscopo, A. S. Velasco Mayorga,
M. Scoppettuolo, F. Milosa, R. M. Critelli, N. Giglio,
F. Scianò, F. Casari, F. Ascari, M. Bianchini,
A. Colecchia, M. Gaggini, F. Vizzutti,
S. Montagnese, F. Schepis
Modena, Padua, Pisa, Florence

29. Socioeconomic Deprivation and Clinical Characteristics of Patients with Newly-Diagnosed Cirrhosis in Italy: Evidence from the SORPRESA Cohort

A. Pasta, S. Cariatì, A. Lombardo, P. Angeli,
S. Incicco, F.R. Ponziani, L. Stella, G.G. Di Costanzo,
D. Angrisani, A. Federico, M. Dallio, G. Pilara,
G. Zaccherini, M. Masarone, F. Morisco, M. Capasso,
N. Coppola, M. Stanzione, A. Aghemo,
S. De Nicola, M. Persico, V. Di Marco, E.G. Giannini
Genoa, Palermo, Padua, Rome, Naples, Bologna,
Salerno, Rozzano (MI)



58th AISF ANNUAL MEETING

SESSIONE POSTER - MARCH 20th, 2026

30. Integrated tissue and liquid biopsy analysis of KDM2A expression in hepatocellular carcinoma

T. Caruso, S. Cesario, I. De Giorgi, F. Salani, F. Pratesi, M.C. Scavuzzo, V. Genovesi, C. Vivaldi, P. Faviana, F. Bartoli, P. Colombatto, F. Di Lella, M.R. Brunetto, G. Cavallini, G. Masi, V. Carloni, L. Gragnani
Pisa, Florence

31. A serology-based algorithm combining total anti-HDV, anti-HDV IgM, and ALT to predict high levels of circulating HDV-RNA

G. Caviglia, E. Dileo, G. Gioiello, S. Limoncelli, A. Olivero, G. Mengozzi, A. Ciancio, A. Loglio, M. Viganò, S. Fagioli, P. Colombatto, B. Coco, M.R. Brunetto, D. Angrisani, A. Galeota Lanza, C. Magni, A. Gori, V. Messina, M. Milella, A. Saracino, L. Marinaro, G. Cariti, V. Cossiga, F. Morisco, S. Cretella, G. Verucchi, E. Biliotti, G. D'Offizi, M. Feasi, E. Pontali, C. Coppola, R. Rapetti, M. Pirisi, A. Izzi, T. Santantonio, V. Di Marco, A. Marrone, N. Coppola, M. Rizzi, A.M. Cattelan, G. A. Niro, P. Toniutto, F. R. Ponziani, L.S. Belli, A. Federico, G. Bertino, M. Barone, M. Puoti, A. Civolani, M. Distefano, L. A. Surace, R. Cozzolongo, E. M. Cela, E. Teti, P. Lampertico,

T. Stroffolini, M. Rizzetto - Turin, Bergamo, Milan, Pisa, Naples, Caserta, Bari, Bologna, Rome, Genoa, Gragnano (NA), Novara, Foggia, Palermo, Padua, San Giovanni Rotondo (FG), Udine, Catania, Cagliari, Siracusa, Lamezia Terme (CZ), Castellana Grotte (BA)

32. Development of new criteria for assessing response to plasma volume expansion at 24 hours in patients with cirrhosis and Acute Kidney Injury

S. Incicco, R. Gagliardi, M. Tonon, V. Calvino, N. Zeni, C. G. Gambino, P. Angeli, S. Piano
Padua

33. Validation of the RETREAT Score for Predicting Hepatocellular Carcinoma Recurrence After Liver Transplantation: Evidence from an Italian Multicenter Cohort

L.A. Natola, V. Paon, M. Vicardi, A. Filice, A. Dalbeni, F. Cattazzo, L. Canova, E. Alimenti, G.M.F. Marini, A. Borin, D. Dondossola, A. Carraro, M. Iavarone, D. Sacerdoti
Verona, Milan

34. PNPLA3 polymorphisms and risk of hepatic and extrahepatic outcomes in MASLD: a systematic review and meta-analysis

C. Celsa, G. Pennisi, A. Tulone, G. Ciancimino, M. Vaccaro, F. Pecorella, G. Di Maria, M. Enea, C. Cammà, S. Petta
Palermo


35. Alcoholic acute-on-chronic liver failure vs alcoholic cirrhosis: clinical outcomes after liver transplantation. A single center experience

C. Sicuro, N. De Maria, R. Cuoghi Costantini, M. Montanari, M. Scoppettuolo, A. Colecchia, F. Di Benedetto, P. Magistri
Modena

36. The Italian PBC Registry: Insights from a Nationwide Cohort Study

E. Nofit, L. Cristoferi, A. Gerussi, D. D'Amato, M.M. G. Festa, E. Bonaiuto, V. Di Marco, F. Azzaroli, E. Dajti, F. Colapietro, P. Lampertico, E. Degaspero, S. Fagioli, M. Viganò, A. Castellaneta, A. De Feudis, E. G. Giannini, S. Labanca, F. Terracciani, G. Raimondo, C. Saitta, M. Russello, M. Cannavò, E. Vanni, A. Risso, F. Morisco,

V. Cossiga, C. Rigamonti, G. F. Manfredi, G. Missale, A. Orlandini, F. Losito, R. Cozzolongo, E. N. Lynch, A. Galli, A. Curto, L. Maroni, M. Brunetto, B. Coco, F. Cerini, F. Pavan, F. Bellanti, S. Quiete, L. Napoli, F. Foschi, A. Mega, M. Zoesch, A. Granito, F. Piscaglia, G. Vitale, M. C. Morelli, V. Pace Palitti, M. Persico, T. Sarcina, L. A. Surace, E. Falbo, R. Viganò, F. D'Amico, D. Alvaro, S. Nardelli, D. Montecalvo, G. Nardone, A. Rocco, G. Vettori, . Moser, C. Ricci, P. Poisa, F. Bronte, A. Affronti, A. Federico, F. Di Nardo, C. Cusumano, C. Agnolon, G. Alagna, I. Cavalli, A. Gobbi, M. C. Bragazzi, R. Venere, A. Mangia, V. Piazzolla, F. Ponziani, F. Fianchi, P. Andreone, F. Gabrielli, T. Zolfino, C. Scudu, G. Niro, R. Cotugno, L. Fabris, A. Lasagni, S. L. Crocè, F. Masutti, L. Chessa, F. Pes, P. Lecis, A. Meneghetti, L. Muratori, M. L. Panico, L. Baiocchi, P. Carni, S. Segato, E. Grassi, F. Capelli, L. Pitotti, L. Abenavoli, G. G. M. Scarlata, A. Baragiotta, F. Marra, F. Biagi, N. Dal Bo', S. Schianchi, M. Beltrami, R. Chiavaroli, M. Graffeo, N. Cazzagon, V. Calvaruso, A. Lleo De Nalda, U. Vespasiani Gentilucci, M. Marzoni, M. Carbone, P. Invernizzi
Monza, Padua, Palermo, Bologna, Rozzano (MI), Milan, Bergamo, Bari, Genoa, Roma, Messina,



58th AISF ANNUAL MEETING SESSIONE POSTER - MARCH 20th, 2026

Catania, Turin, Naples, Novara, Parma, Castellana Grotte (BA), Florence, Ancona, Pisa, Foggia, Faenza (RA), Bolzano, Pescara, Salerno, Lamezia Terme (CZ), Trento, Brescia, Verona, Sassari, Cremona, Latina, San Giovanni Rotondo (FG), Modena, Cagliari, Trieste, Monserrato (CA), Bassano del Grappa (VI), Varese, Legnano (MI), Catanzaro, Pordenone, Treviso, Reggio Emilia

37. SAMOTHRACE: AI-Supported Telemonitoring to Detect Early Decompensation in Cirrhosis Awaiting Liver Transplantation

C.M. Giacchetto, G. Enea, V. Lo re, B. Magro, G. Pietrosi, D. Terzo, D. Lo bello, D. Bellavia, N. Rizzitello, M. Larafa, E. Randazzo, M. Pinzani, S. Gruttadauria, A. Galante, G. Martucci
Palermo

38. MASLD-related hepatocellular carcinoma in cirrhotic and non-cirrhotic patients: a realworld analysis from the ITA.Li.Ca. cohort

L. Ragozzino, A. Mastro, T. V. Li Cavoli, A. Toscano, T. Zurli, V. Adotti, F. Marra
Florence, Messina

39. Assessment of Hepatocellular Carcinoma Risk in Non-Cirrhotic Individuals with HCV Infection Following SVR Achievement with DAA Therapy: A Single-Center Retrospective Longitudinal Observational Analysis

A. Salvaderi, L. Maiocchi, M. Gerola, P. Angelini, S. Lerta, G. P. Peroò, G. Sangaletti, S. Corallo, A. Lasagna, B. Caccia, G. Albi, R. Bruno, V. Zuccaro
Pavia

40. Impact of Incidental Computed Tomographic Ischemic Areas After Liver Transplantation: Associations with Donor Type, Perfusion Strategy, and Clinical Outcomes

D. Pagano, G. Mamone, F. di Francesco, C. Celsa, A. Galante, M. C. Giacchetto, S. Li Petri, C. Camma', N. Di Lorenzo, S. Gruttadauria – Palermo

41. Enhancing Guideline-Concordant Decision Support in Hepatology: A Retrieval-Augmented Generation Framework Evaluated Across Five Major Hepatology Clinical Domains

S. Kresevic, F. Orbosuè, M. Gulotta, L. Fusaro, A. Distefano, A. Accardo, M. Ajcevic, L.S. Crocè
Trieste

42. Endoscopic ultrasound Guided Portal Pressure Gradient: Prognostic Utility and Concordance With the Hepatic Venous Pressure Gradient

L. Giuli, A. Larghi, G. Rizzatti, M. Pallozzi, C. Cavallo, G. Venturini, F. R. Ponziani, B.E. Annicchiarico, G. Tripodi, A. Contegiacomo, R. Iezzi, R. Talerico, A. Gasbarrini, F. Santopaolo
Rome

43. A Multi-Agent Large Language Model Framework that Simulates a Multidisciplinary Tumor Board for Hepatocellular Carcinoma Management

M. Giuffrè, F. Ma, A. Visintin, L. Fusaro, M. Gulotta, M. Sartori, F. Masutti, L. S. Crocè
New Haven (USA), Trieste

44. Platelets mirror disease severity in Metabolic dysfunction-Associated Steatotic Liver Disease


M. Zoncapè, M. Castelli, A. Meneguzzi, A. Mantovani, D. Sacerdoti, P. Minuz, A. Dalbeni
Padua, Verona

45. A machine learning-powered tool to characterize cholangiocarcinoma prognosis

G. De Sario, L. Manganaro, G. Carpino, F. Biancaniello, M.C. Bragazzi, M. Franchitto, M. Franchitto, S. Paradiso, T. De Luca, D. Overi, A. Ducato, C. Ferrari, G. Tortorelli, F. Ardito, A.M. De Rose, F. Razionale, F. Giuliani, G.L. Grazi, E. Gaudio, D. Alvaro, V. Cardinale
Rome, Turin, Florence, Boston (USA)

46. Diagnostic yield of a targeted Next Generation Sequencing (NGS) cholestasis-gene panel in adult with unexplained cholestatic liver disease: a multicenter Italian cohort study

L. Cristoferi, D. D'Amato, F. Terracciani, L. Ronzoni, P. Colombatto, A. Curto, S. Labanca, C. De Benedittis, S. Nardelli, B. Coco, E. Mensi, A. Gerussi, F. Malinverno, E. N. Lynch, D. Montecalvo, L. Casella, M. Distefano, G. Alagna, M. Viganò, A. Cereda, F. Bertola, A. Caserta, V. Calvaruso, C. Rigamonti, D. Alvaro, M.R. Brunetto, A. Galli, L. Valenti, E. G. Giannini, M. Carbone, P. Invernizzi, U. Vespasiani Gentilucci
Monza, Rome, Milan, Pisa, Florence, Genoa, Novara, Siracusa, Sassari, Bergamo, Palermo



58th AISF ANNUAL MEETING SESSIONE POSTER - MARCH 20th, 2026

47. Early detection of minimal hepatic encephalopathy using wearable sensors

C. Asero, M. S. Franzè, C. Ligresti, A. Battaglia,
C. Saitta, R. Filomia, G. Caccamo, C. Pitrone,
D. Milone, C. De Marchis, I. Cacciola
Messina, Palermo

48. Non-invasive tests for liver fibrosis are inaccurate to screen for advanced fibrosis in general adult population

M. Tonon, V. Calvino, R. Gagliardi, S. Incicco, N. Zeni,
V. Santori, A. Accetta, G. Antonacci, A. Martini,
M. Crescenzi, A. Zanetti, P. Angeli, S. Piano
Padua

49. From Cure to Complexity: Post-SVR Liver and Metabolic Trajectories in Diabetic Patients

C. Asero, M. S. Franzè, T. Maltese, A. La Spada,
D. Lombardo, C. Grisanti, R. Filomia, G. Caccamo,
C. Pitrone, C. Saitta, T. Pollicino, I. Cacciola
Messina

50. Metabolome analysis revealed red flag signatures for the identification of MASLD risk across patients with dysmetabolic traits

M. Longo, M. Meroni, E. Paolini, G. Paoella,
R. Lombardi, V. Flagiello, J. Avagliano, C. Garavaglia,
E. Polledri, R. Mercandate, P. Gallo, F. Terracciani,
S. Fustinoni, C. Agostoni, M. Gomaraschi,
U. Vespasiani-Gentilucci, A. Fracanzani,
P. Dongiovanni
Milan, Rome, Naples, Salerno

51. Stereotactic Body Radiotherapy for the treatment of HCC: a single center experience

C. Mazzairelli, A. Maver, L. S. Belli, M. Palazzi,
F. Bracco, A. Casbarra, F. Tosi, K. Bencardino,
I. Vicentin, C. Sgrazzutti, A. Lauterio, D. Sibio
Milan

52. Cabozantinib for Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Multicenter Clinical Experience

C. Mazzairelli, F. Tosi, G. Mauri, M. Sagasta,
C. Di Benedetto, E. Alimenti, M. A. Iavarone,
D. Costantino, M. De Giorgio, L. S. Belli
Milan, Bergamo

53. Prevalence and Determinants of Elevated FIB-4 in Adults from Primary Care

M. Montori, D. Balducci, G. M. Corradini, M. Ricci, E. Fiorini, P. Core, P. Lodolini, A. Marracino, M. Luzi, M. D. Giulioni, G. Sampaolo, M. Zucchi, A. Pini, R. Deliberato, E. Zucchi, A. Di Giovannangelo, A. Lucarelli, G. Svegliati Baroni - Ancona

54. Comparative analysis of albumin microheterogeneity and metabolic signatures in portal, hepatic, and peripheral circulation: prognostic implications in patients with cirrhosis undergoing TIPS

M. Baldassarre, S. Di Cola, S. Nardelli, G. Cusi, E. Pompili, G. Tedesco, M. Naldi, A. Perrone, W. Mensah, M. Bartolini, P. Caraceni, M. Merli
Bologna, Rome

55. The Role of Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: from neoplastic portal invasion to extrahepatic metastasis a prospective study from ARTE dataset

F. Cattazzo, M. Bevilacqua, M. Vicardi, V. Di Maria, M. Iavarone, G. Cabibbo, F. Marra, C. Vivaldi, F.R. Ponzani, A. Palloni, S. Lonardi, L. Lani, P.


Federico, G. Svegliati-Baroni, T. Pressani, L. Ielasi, C. Mazzearelli, S. De Lorenzo, R. Sacco, M. Bruccoleri, C. Celsa, C. Campani, G. Masi, L. Stella, P. Toniutto, R. Villani, M. Dibetto Dimondini, F. Tovoli, D. Sacerdoti, A. Auriemma, A. Dalbeni
Verona, Milan, Palermo, Firenze, Pisa, Roma, Bologna, Padova, Napoli, Ancona, Rozzano (MI), Faenza (RA), Foggia, Udine

56. Long-term cohort analysis of HBV Basic Core Promoter, Pre-Core, and Core Region heterogeneity

D. Cavallone, G. Ricco, P. Colombatto, B. Coco, B. Vianello, A. Cali, F. Bonino, M. R. Brunetto
Pisa

57. HCV testing and linkage-to-care practices in a tertiary hospital in Southern Italy underscore the need for routine screening and treatment programs

P. Torre, E. Serretiello, G. Di Siervi, E. Vaccaro, T. Sarcina, M. Festa, V. Folliero, G. Boccia, M. Masarone, G.L. Franci, M. Persico
Salerno, Baronissi (SA)



58th AISF ANNUAL MEETING

SESSIONE POSTER - MARCH 20th, 2026

58. Hemodynamic alterations of porto-sinusoidal vascular disease (PSVD) with portal hypertension evaluated by Doppler-sonography

M. Bevilacqua, F. Cattazzo, F. Smaldone, M. Ferrari, B. Vescovi, S. Marin, S. Grisenti, S. Romeo, A. Filice, L. Natola, V. Paon, D. Ieluzzi, A. Dalbeni, A. Mantovani, D. Sacerdoti
Verona

59. The burden of cirrhosis admissions with extrahepatic organ failures in Italy

R. Gagliardi, A. Barone, S. Incicco, M. Tonon, C.G. Gambino, V. Calvino, A. Accetta, V. Santori, N. Zeni, P. Angeli, S. Piano
Padua

60. Non-invasively estimated risk of clinically significant portal hypertension is a predictor of hepatic decompensation in compensated advanced chronic liver disease of different etiologies

C. Rigamonti, C. Tacchelli, P. Lorenzon, G.F. Manfredi, C. De Benedittis, S. Casella, M.E. Burlone, M. Pirisi
Novara

61. ESC and CARDIOSOR scores as easy tools to stratify cardiovascular risk in patients with HCC treated with atezolizumab/bevacizumab

M. Dibetto Rimondini, B. Stefanini, L. Rimassa, M. Iavarone, G. Cabibbo, F. Marra, C. Vivaldi, A. Dalbeni, F. R. Ponziani, A. Palloni, S. Lonardi, L. Lani, P. Federico, G. Svegliati-Baroni, T. Pressiani, L. Ielasi, C. Mazzearelli, S. De Lorenzo, R. Sacco, M. Bruccoleri, C. Celsa, A. Auriemma, L. Stella, P. Toniutto, R. Villani, A. Granito, F. Tovoli, F. Piscaglia
Bologna, Pieve Emanuele (MI), Rozzano (MI), Milan, Palermo, Florence, Pisa, Verona, Rome, Padoua, Naples, Ancona, Faenza (RA), Foggia, London (UK), Udine

62. Multidimensional frailty assessment of liver transplant recipients with long term follow-up (>20 years): an ELITA/ELTR study

R. Viganò, A. Carvalho, A. Ferrarese, C. Becchetti, D.P. Bernasconi, F. Berardi, C. Di Benedetto, L. Pasulo, S. Jacobs, N. Sperduti, J. Ursic-Bedoya, A. Della Penna, L.M.A. Patetta, C. Mazzearelli, M. Cucco, M. Sagasta, M. Triolo, G. Vasta, A. Iozzi, G.P. Pageau, L. Gheorghe, V. Giannelli, S. Nadalin, P. Lampertico, S. Fagioli, G. Germani, M. Cesari, M. Berenguer, L.S. Belli

Milan, Valencia (Spain), Padoua, Monza, Rozzano (MI), Bergamo, Bucharest (Romania), Rome, Montpellier (France), Tübingen (Germany), Geneva (Switzerland)

63. Lymphoproliferative disorders following liver transplantation: a single center experience over 25 year

L. Pasulo, A. Barbui, R. Hakimizad, F. Leonardi, G. Mangia, P. Stroppa, M. Vigano', S. Camagni, L. Licini, S. Fagiuoli - Bergamo, Milan

64. Assessment of sarcopenia in compensated liver cirrhosis by muscle ultrasound-based approach

R. Bonica, S. Como, A. Rizzo, M. Soresi, M. Pace, R. Chianetta, P. Cimino, R. Citarrella, L. Giannitrapani, M. Galia, A. Licata
Palermo

65. Burden of MASLD and impact of social determinants of health in an irregular migrant population

G. Di Franco, M. Soresi, T. Di Franco, G. Rizzo, M. Affronti, E. Piccione, A. Licata, M. Barbagallo, L. Giannitrapani
Palermo

66. Prothrombin induced by vitamin K absence-II

(PIVKA-II) emerges as the strongest independent prognostic biomarker for hepatocellular carcinoma: a real-world multicenter study


F. Damone, G. P. Caviglia, P. Colombatto, F. Oliveri, M. Guariglia, G. Ricco, S. Gaia, V. Romagnoli, D. Cavallone, E. Rolle, P. Carucci, F. Faita, F. Bonino, M. R. Brunetto
Pisa Turin

67. Radioembolization-Driven Downstaging in HCC: Five-Year Survival and Recurrence in Transplanted Patients

V. Giannelli, M. Spigaroli, C. Telesca, R. Cianni, G. Ventroni, N. Guglielmo, M. Colasanti, P. Riu, S.

68. Effect of proton pump inhibitors exposure and discontinuation on infection outcomes in cirrhosis

M.S. Franzè, C. Asero, G. Caccamo, R. Filomia, C. Pitrone, C. Saitta, I. Cacciola
Messina



58th AISF ANNUAL MEETING

SESSIONE POSTER - MARCH 20th, 2026

69. AFP and PIVKA-II monthly dynamics in HCC patients undergoing locoregional and systemic therapies: implication for an earlier identification of responders

F. Damone, P. Colombatto, G. Ricco, F. Oliveri, V. Romagnoli, D. Cavallone, G. Petralli, F. Bonino, M.R. Brunetto
Pisa

70. Implementation of a multidisciplinary care pathway improves MASLD screening and cardiometabolic management

M. Cucco, R. De Maria, C. Pavanello, L. Cesarini, G. Mombelli, A. Alberti, F. Bertuzzi, L.S. Belli, L. Calabresi
Milan

71. Nutritional Status, Physical Activity, and Symptom Burden in Outpatients with Stable Polycystic Liver Disease

S. Di Cola, S. Khan, L. Lapenna, A. Vignone, V. Cardinale, M. Merli
Rome

72. Liver transplantation for acute liver failure in North Italy Transplant program area: clinical and epidemiological features over 35 years

C. Scalarnogna, T. M. De Feo, M. . Donato, E. Sguazzini, R. Torelli, A. Longobardi, C. Dibenedetto, C. Quintini, E. Andorno, L. Pasulo, P. Stroppa, D. Pinelli, A. Lauterio, R. Viganò, U. Cillo, P. Burra, G. Conte, U. Baccarani, A. Carraro, M. Cardillo on Behalf of North Italy Transplant program (NITp) Liver and Intestine Transplant Working Group
Milan, Genoa, Bergamo, Padua, Ancona, Udine, Verona

73. Partial Splenic Embolization for the Prevention of Variceal Rebleeding in Patients Unsuitable for OLTx, TIPS, and Endovascular Treatment: Safety and Mortality

M. Bianchini, C. Gualandri, D. Saltini, T. Guasconi, A. Piscopo, G. Lo Cascio, A. S. Velasco Mayorga, F. Casari, G. Battinelli, F. Ascari, F. Prampolini, C. Caporali, F. Schepis
Modena

74. Lipidomic profiling of Metabolic dysfunction-Associated Steatohepatitis (MASH): identifying lipid biomarkers for detection and stratification of disease severity

F. Gabrielli, L. Bertarini, F. Pellati, P. Andreone, P. Ventura
Modena

75. Early Acute Rejection After Liver Transplantation in Patients Treated With Durvalumab:

Preliminary Findings From the LIRICA and LITALHICA Protocols

E. Nieddu, A. Furlanetto, R. Romagnoli, D. Ghinolfi, S. Gruttadauria, A. Lauterio, A. Carraro, G.M. Ettorre, M. Vivarelli, M. Cescon, D. Pinelli, F. Di Benedetto, U. Baccarani, A.W. Avolio, G. Vennarecci, E. Rosso, C. Naldini, C. De Nardi, M. Botton, I. Billato, J. Lanari, M. Gambato, F. Bergamo, S. Trapani, G. Feltrin, C. Mescoli, G. De Conti, P. Burra, U. Cillo, E. Gringeri
Padua, Turin, Pisa, Palermo, Milan, Verona, Rome, Ancona, Bologna, Bergamo, Modena, Udine, Naples

76. Anti-HBc positivity is associated with worse tumour features and reduced survival in HBsAg-negative patients with hepatocellular carcinoma

C. Saitta, M. S. Franzè, A. Toscano, C. Asero, G. Caccamo, R. Filomia, C. Pitrone, I. Cacciola
Messina

77. Developing a Predictive Model of Prognosis After Curative-Intent Resection of Intrahepatic Cholangiocarcinoma

M. Botton, E. Nieddu, J. Lanari, A. Furlanetto, E. Rosso, C. Naldini, C. De Nardi, M. Polacco, D. Bassi, F. E. D'Amico, R. Boetto, A. Dolcet, A. Bertacco, A. Marchini, I. Billato, F. Bergamo, C. Soldà, M. D. Rizzato, S. Lonardi, C. Mescoli, U. Cillo, E. Gringeri – Padua

78. Revisiting national allocation policies for combined liver transplantation: time for acting

D. Pagano, A. Tropea, F. Di Francesco, S. Li Petri, P. Bonsignore, S. Calamia, I. Vitale, I. Vella, C. Accardo, A. Bertani, A. Galante, B. Buscemi, S. Gruttadauria
Palermo



58th AISF ANNUAL MEETING

SESSIONE POSTER - MARCH 20th, 2026

79. Identification of a duodenal RNA signature in patients with MASLD-cirrhosis

F. Salomone, A. Scamporrino, A. Filippello, S. Piro, S. Di Mauro - Catania, Enna

(USA), Hong Kong (China), Birmingham (UK), Seoul (Republic of Korea), Amiens (France)

80. Machine Learning Prediction of Liver Fibrosis in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease

S. Petta, G. Pennisi, C. Celsa, S. Messaoudi, E. Tsochatzis, E. Bugianesi, M. Yoneda, M. Zheng, H. Hagström, J. Boursier, J.L. Calleja, G.B. Goh, W. Chan, R. Gallego-Durán, A. J. Sanyal, V. de Lédinghen, P. N. Newsome, J. Fan, L. Castéra, M. Lai, C. Fournier-Poizat, G. L. Wong, A. Armandi, A. Nakajima, Y. Shang, M. de Saint-Loup, E. Llop, K.K.J. Teh, C. Lara-Romero, A. Asgharpour, M.S. Chan, M. Romero-Gomez, H. Lin, S. U. Kim, T.C. Yip, V. Calvaruso, J.C. Lai, B. Yang, H.W. Lee, G. Di Maria, M. Enea, S. Contino, V.W. Wong, G. Cirrincione, C. Cammà
Palermo, London (UK), Turin, Yokohama (Japan), Wenzhou (China), Stockholm (Sweden), Angers (France), Madrid (Spain), Singapore, Kuala Lumpur (Malaysia), Seville (Spain), Richmond (USA), Paris (France), Shanghai (China), Clichy (France), Boston

Ludovico Abenavoli	<i>Catanzaro</i>
Giovanni Addolorato	<i>Rome</i>
Alessio Aghemo	<i>Milan</i>
Domenico Alvaro	<i>Rome</i>
Angelo Armandi	<i>Turin</i>
Clara Balsano	<i>L'Aquila</i>
Michele Bartoletti	<i>Milan</i>
Chiara Becchetti	<i>Milan</i>
Sherrie Bhoori	<i>Milan</i>
Maurizia Rossana Brunetto	<i>Pisa</i>
Elisabetta Bugianesi	<i>Turin</i>
Patrizia Burra	<i>Padua</i>
Giuseppe Cabibbo	<i>Palermo</i>
Vincenza Calvaruso	<i>Palermo</i>
Calogero Cammà	<i>Palermo</i>


Paolo Caraceni	<i>Bologna</i>
Marco Carbone	<i>Milan</i>
Nora Cazzagon	<i>Padua</i>
Barbara Coco	<i>Turin</i>
Massimiliano Conforti	<i>Turin</i>
Nicola Coppola	<i>Naples</i>
Laura Cristoferi	<i>Milan</i>
Laura Crocetti	<i>Pisa</i>
Roberta D'Ambrosio	<i>Milan</i>
Roberto de Franchis	<i>Milan</i>
Nicola De Maria	<i>Modena</i>
Elisabetta Degasperi	<i>Milan</i>
Marco Distefano	<i>Siracusa</i>
Stefano Fagiuoli	<i>Bergamo</i>
Alessandro Federico	<i>Naples</i>



FACULTY

Alberto Ferrarese	<i>Padua</i>
Paolo Gallo	<i>Rome</i>
Antonio Gasbarrini	<i>Rome</i>
Giacomo Germani	<i>Padua</i>
Alessio Gerussi	<i>Milan</i>
Valerio Giannelli	<i>Rome</i>
Edoardo Giovanni Giannini	<i>Genoa</i>
Stefano Gitto	<i>Florence</i>
Enrico Gringeri	<i>Padua</i>
Pietro Invernizzi	<i>Milan</i>
Loreta Kondili	<i>Rome</i>
Vincenzo La Mura	<i>Milan</i>
Quirino Lai	<i>Rome</i>
Pietro Lampertico	<i>Milan</i>
Ana Lleo	<i>Milan</i>

Alessandro Loglio	<i>Bergamo</i>
Fabio Marra	<i>Florence</i>
Giuseppe Marrone	<i>Rome</i>
Silvia Martini	<i>Turin</i>
Mario Masarone	<i>Naples</i>
Chiara Mazzarelli	<i>Milan</i>
Luca Miele	<i>Rome</i>
Sara Montagnese	<i>Padua</i>
Cristina Morelli	<i>Bologna</i>
Filomena Morisco	<i>Naples</i>
Duilio Pagano	<i>Palermo</i>
Giovanni Perricone	<i>Milan</i>
Marcello Persico	<i>Salerno</i>
Paolo Persona	<i>Padua</i>
Salvatore Petta	<i>Palermo</i>



FACULTY

Salvatore Piano	Milan
Fabio Piscaglia	Bologna
Francesca Romana Ponziani	Rome
Maria Rendina	Bari
Cristina Rigamonti	Novara
Vincenzo Ronca	Milan
Francesco Paolo Russo	Padua
Rodolfo Sacco	Foggia
Dario Saltini	Modena
Filippo Schepis	Modena
Marco Senzolo	Padua
Debbie Shawcross	London, UK
Giovanni Squadrito	Messina
Gianluca Svegliati Baroni	Ancona
Pierluigi Toniutto	Udine

Giulia Tosetti	Milan
Francesco Tovoli	Bologna
Laura Turco	Bologna
Luca Valenti	Milan
Umberto Vespasiani Gentilucci	Rome
Mauro Viganò	Bergamo
Alessandro Vitale	Padua
Francesco Vizzutti	Florence
Zobair Younossi	Washington, USA
Giacomo Zaccherini	Bologna
Alberto Zanetto	Padua
Anna Linda Zignego	Florence
Valentina Zuccaro	Pavia



INFORMAZIONI GENERALI

SEDE DEL MEETING

Centro Congressi Auditorium della Tecnica

Viale Umberto Tupini, 65 • 00144 Roma

SEGRETERIA ORGANIZZATIVA



Viale Maresciallo Pilsudski, 118 • 00197 Roma

Tel. 06 845431 • E-mail roma@aristeia.com

Web www.aristeia.com

PROVIDER E.C.M. (ID 1547)



AISF - Associazione Italiana per lo Studio del Fegato

Viale Maresciallo Pilsudski, 118 • 00197 Roma

Tel. 06 86399303 • E-mail info@webaisf.org


Web www.webaisf.org



ATTESTATO DI PARTECIPAZIONE

L'attestato di partecipazione sarà disponibile per il download sulla piattaforma internet:

<https://online.aristeia.com/login>



ISCRIZIONI - PRE MEETING COURSE

SOCI AISF

Per i Soci AISF in regola con il versamento delle quote associative la quota di partecipazione è:

- < 35 anni € 50,00 (inclusa IVA 22%)
- > 35 anni € 120,00 (inclusa IVA 22%)

ARISTEA PASS >

Sarà indispensabile aver precedentemente regolarizzato la propria posizione associativa entrando nell'**Area Soci** col proprio profilo utente.

PAGAMENTO QUOTA AISF >

NUOVI SOCI AISF

Per accedere in qualità di Socio AISF all'Evento Formativo è necessario iscriversi all'AISF. L'iscrizione all'AISF dà diritto alla partecipazione gratuita alle Riunioni Istituzionali "Riunione Generale Annuale", "Riunione Monotematica" e "Special Conference", all'abbonamento gratuito alla rivista Digestive and Liver Disease ed a ricevere qualsiasi informazione relativa all'attività dell'Associazione.

ISCRIZIONE ALL'AISF >

NON SOCI AISF

€ 240,00 (inclusa IVA 22%)

Le quote di iscrizione includono: l'accesso alle Sessioni Scientifiche, *coffee breaks*, *lunches*, l'attestato di partecipazione, l'attestato E.C.M. (se conseguito).


ARISTEA PASS >

Termine per Iscrizione: **20 Febbraio 2026**

Al termine dell'iscrizione, riceverete un e-badge via e-mail. Vi preghiamo di conservarlo sul vostro smartphone e, in sede di evento, scansare il QR code presente sull'e-badge ai terminali self-service nella zona di benvenuto e stampare quindi il badge di accesso ai lavori congressuali.

CANCELLAZIONE E RIMBORSI

Le cancellazioni pervenute entro il giorno 20 Febbraio 2026, tramite comunicazione scritta alla Segreteria Organizzativa, daranno diritto ad un rimborso totale dell'importo versato, detratto l'importo di € 15,00 per spese amministrative. Superata tale data non saranno riconosciuti rimborsi. I rimborsi saranno effettuati solo dopo il termine dell'Evento.



E.C.M. - PRE MEETING COURSE

E.C.M. - EDUCAZIONE CONTINUA IN MEDICINA E DESTINATARI ATTIVITÀ FORMATIVA

Il Corso è stato inserito dall'AISF – Provider accreditato dalla Commissione Nazionale per Formazione Continua con il numero di accreditamento 1547 – nel proprio piano formativo 2026 nell'ambito del Programma Nazionale E.C.M. (Educazione Continua in Medicina).

L'Evento Formativo è stato accreditato **per n. 500 partecipanti**, per la categoria professionale Medico Chirurgo, specializzata per le seguenti discipline: Gastroenterologia, Malattie Infettive, Medicina Interna, Chirurgia Generale, Microbiologia e Virologia, Anatomia Patologica, Medicina Generale - Medici di Famiglia.

I crediti saranno rilasciati esclusivamente ai partecipanti appartenenti alle professioni ed alle discipline indicate che rientreranno nel numero massimo di partecipanti per il quale l'evento è stato accreditato.


OBIETTIVO FORMATIVO

Applicazione nella pratica quotidiana dei principi e delle procedure dell'evidencebased practice (EBM - EBN - EBP)

VALUTAZIONE E CERTIFICAZIONE DEI CREDITI E.C.M.

L'attestazione dei crediti è subordinata alla partecipazione effettiva all'intero evento formativo, nella misura del 100%, ed alla compilazione dell'Autodichiarazione obbligatoria e della Scheda di Valutazione evento.

L'attestato, riportante il numero di crediti assegnati, verrà pertanto rilasciato dopo avere effettuato tali verifiche e sarà quindi disponibile online – entro 60 giorni dopo la chiusura dell'evento – sul sito web www.aris-teaeducation.it. L'accesso alla documentazione sarà attivato al termine di ogni Sessione E.C.M. per le successive 72 ore. Il mancato rispetto dei suindicati requisiti non darà diritto ai crediti E.C.M., ma solamente all'attestato di partecipazione.



ISCRIZIONI - ANNUAL MEETING

SOCI AISF

Per i Soci AISF in regola con il versamento delle quote associative la partecipazione è gratuita. Sarà indispensabile regolarizzare la propria posizione associativa entrando nell'Area Soci del sito web AISF col proprio profilo utente.

PAGAMENTO QUOTA AISF >

Per iscriversi all'evento cliccare qui:

ARISTEA PASS >

NUOVI SOCI AISF

Per accedere in qualità di Socio AISF all'Evento Formativo è necessario iscriversi all'Associazione cliccando qui:

ISCRIZIONE ALL'AISF >

L'iscrizione all'AISF dà diritto alla partecipazione gratuita alle Riunioni Istituzionali "Riunione Generale Annuale", "Riunione Monotematica" e "Special Conference", all'abbonamento gratuito alla rivista Digestive and Liver Disease ed a ricevere qualsiasi informazione relativa all'attività dell'Associazione.

NON SOCI AISF

€ 300,00 (inclusa IVA 22%)

Le quote di iscrizione includono: l'accesso alle Sessioni Scientifiche, *coffee breaks*, *lunches*, l'attestato di partecipazione, l'attestato E.C.M. (se conseguito).

Per iscriversi all'evento clicca qui:

ARISTEA PASS >

Termine per Iscrizione: **20 Febbraio 2026**

Al termine dell'iscrizione, riceverete un e-badge via e-mail. Vi preghiamo di conservarlo sul vostro smartphone e, in sede di evento, scansionare il QR code presente sull'e-badge ai terminali self-service nella zona di benvenuto e stampare quindi il badge di accesso ai lavori congressuali.

Cancellazione e rimborsi

Le cancellazioni pervenute entro il giorno 20 Febbraio 2026, tramite comunicazione scritta alla Segreteria Organizzativa, daranno diritto ad un rimborso totale dell'importo versato, detratto l'importo di € 15,00 per spese amministrative. Superata tale data non saranno riconosciuti rimborsi. I rimborsi saranno effettuati solo dopo il termine dell'Evento.



E.C.M. - ANNUAL MEETING

E.C.M. - EDUCAZIONE CONTINUA IN MEDICINA E DESTINATARI ATTIVITÀ FORMATIVA

Il Congresso è stato inserito dall'AISF – Provider accreditato dalla Commissione Nazionale per Formazione Continua con il numero di accreditamento 1547 – nel proprio piano formativo 2026 nell'ambito del Programma Nazionale E.C.M. (Educazione Continua in Medicina).

L'Evento Formativo è stato accreditato **per n. 500 partecipanti**, per la categoria professionale Medico Chirurgo, specializzata per le seguenti discipline: Gastroenterologia, Malattie Infettive, Medicina Interna, Chirurgia Generale, Microbiologia e Virologia, Anatomia Patologica, Medicina Generale - Medici di Famiglia. I crediti saranno rilasciati esclusivamente ai partecipanti appartenenti alle professioni ed alle discipline indicate che rientreranno nel numero massimo di partecipanti per il quale l'evento è stato accreditato.

OBIETTIVO FORMATIVO

Applicazione nella pratica quotidiana dei principi e delle procedure dell'evidencebased practice (EBM - EBN - EBP)

VALUTAZIONE E CERTIFICAZIONE DEI CREDITI E.C.M.

L'attestazione dei crediti è subordinata alla partecipazione effettiva all'intero evento formativo, nella misura del 100%, ed alla compilazione dell'Autodichiarazione obbligatoria e della Scheda di Valutazione evento.

L'attestato, riportante il numero di crediti assegnati, verrà pertanto rilasciato dopo avere effettuato tali verifiche e sarà quindi disponibile online – entro 60 giorni dopo la chiusura dell'evento – sul sito web www.aris-teaeducation.it

L'accesso alla documentazione sarà attivato al termine di ogni Sessione E.C.M. per le successive 72 ore.

Il mancato rispetto dei suindicati requisiti non darà diritto ai crediti E.C.M., ma solamente all'attestato di partecipazione.